0001607062-19-000457.txt : 20191119 0001607062-19-000457.hdr.sgml : 20191119 20191119114832 ACCESSION NUMBER: 0001607062-19-000457 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191119 DATE AS OF CHANGE: 20191119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clinigence Holdings, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53862 FILM NUMBER: 191229731 BUSINESS ADDRESS: STREET 1: 55 IVAN ALLEN JR. BLVD STREET 2: NW #875 CITY: ATLANTA STATE: GA ZIP: 30308 BUSINESS PHONE: 631-670-6777 MAIL ADDRESS: STREET 1: 55 IVAN ALLEN JR. BLVD STREET 2: NW #875 CITY: ATLANTA STATE: GA ZIP: 30308 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 10-Q 1 igmb093019form10q.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly period ended September 30, 2019

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from to

Commission file number 000-53862

Clinigence Holdings, Inc.

(Formerly known as iGambit Inc.)

(Exact name of small business issuer as specified in its charter)

Delaware		11-3363609
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

55 Ivan Allen Jr. Blvd. NW, Suite 875

Atlanta, Georgia, FL 30308
(Address of Principal Executive Offices) (Zip Code)

(678) 607-6393
(Issuer’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value	IGMBD	OTCMKTS

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☐		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The Registrant had 4,627,721 (not including 20 thousand shares held in treasury) shares of the Registrant’s $0.001 par value common stock outstanding.

Clinigence Holdings, Inc.
Form 10-Q

Part I — Financial Information
Item 1. Financial Statements:
Unaudited Condensed Consolidated Balance Sheets	2
Unaudited Condensed Consolidated Statements of Operations	3
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity	4
Unaudited Condensed Consolidated Statements of Cash Flows	5
Unaudited Condensed Notes to Consolidated Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3. Quantitative and Qualitative Disclosures About Market Risk	28
Item 4. Controls and Procedures	28
Part II — Other Information
Item 1. Legal Proceedings	29
Item 1A. Risk Factors	29
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3. Defaults upon Senior Securities	29
Item 4. Removed and Reserved	29
Item 5. Other Information	29
Item 6. Exhibits	30
EX-31.1
EX-31.2
EX-32.1
EX-32.2

PART I — FINANCIAL INFORMATION

Item 1 — Financial Statements

CLINIGENCE HOLDINGS, INC.
(FORMERLY KNOWN AS IGAMBIT INC.)
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)


		SEPTEMBER 30,			DECEMBER 31,
		2019			2018
ASSETS
Current assets
Cash	$	10,029		$	369
Accounts receivable		10,000			14,871
Inventory		26,988			27,073
Prepaid expenses		5,971			—
Total current assets		52,988			42,313

Other assets
Property and equipment, net		1,376			2,118
Intangible assets, net		2,050,113			2,572,015
Deposits		300			2,020
	$	2,104,777		$	2,618,466

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses	$	740,465		$	480,270
Accrued interest on notes payable		27,165			32,265
Amounts due to related parties		128,476			145,367
Deferred revenue		600			9,192
Notes payable		495,593			52,500
Convertible notes payable, net		72,546			377,611
Derivative liability		—			288,242
Total current liabilities		1,464,845			1,385,447

Stockholders' equity
Preferred stock, $.001 par value; authorized - 100,000,000 shares;issued and outstanding - 0 shares in 2019 and 2018, respectively		—			—
Common stock, $.001 par value; authorized - 800,000,000 shares; 797,108 and 429,720 shares issued and 777,108 and 409,720 shares outstanding (net of treasury shares) as of September 30, 2019 and December 31, 2018, respectively
Additional paid-in capital		15,605,460			14,695,403
Accumulated deficit		(13,966,325	)		(12,462,814	)
		1,639,932			2,233,019
Less: Treasury stock; 20,000 shares, at cost		(1,000,000	)		(1,000,000	)
Total stockholders' equity		639,932			1,233,019
	$	2,104,777		$	2,618,466

See accompanying notes to the condensed consolidated financial statements.

CLINIGENCE HOLDINGS, INC.
(FORMERLY KNOWN AS IGAMBIT INC.)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)


	THREE MONTHS						NINE MONTHS
	ENDED						ENDED
	SEPTEMBER 30,						SEPTEMBER 30,
	2019			2018			2019			2018
Sales	$	7,550		$	22,582		$	19,175		$	30,500
Cost of sales		10,042			7,834			26,336			23,658
Gross profit (loss)		(2,492	)		14,748			(7,161	)		6,842

Operating expenses
General and administrative expenses		187,295			207,793			576,512			752,930
Amortization		173,967			173,967			521,902			521,902
Total operating expenses		361,262			381,760			1,098,414			1,274,832

Loss from operations		(363,754	)		(367,012	)		(1,105,575	)		(1,267,990	)

Other income (expenses)
Change in fair value of derivative liability		—			76,091			98,944			(128,100	)
Loss on extinguishment of debt		—			(95,464	)		(262,566	)		(233,734	)
Interest expense		(9,995	)		(222,134	)		(234,314	)		(314,975	)
Total other income (expenses)		(9,995	)		(241,507	)		(397,936	)		(676,809	)

Net loss	$	(373,749	)	$	(608,519	)	$	(1,503,511	)	$	(1,944,799	)
Basic and fully diluted loss per common share:
Net loss per common share	$	(.48	)	$	(2.09	)	$	(2.13	)	$	(7.39	)
Weighted average common shares outstanding - basic and fully diluted		777,108			291,514			704,331			263,269

See accompanying notes to the condensed consolidated financial statements.

CLINIGENCE HOLDINGS, INC.
(FORMERLY KNOWN AS IGAMBIT INC.)
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
(UNAUDITED)



	Common stock
	Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Treasury Stock			Totals
Balances, December 31, 2017		252,393	$	252	$	13,017,292	$	(9,648,569	)	$	(1,000,000	)	$	2,368,975
Common stock issued for cash		1,500		2		14,998		—			—			15,000
Notes payable and accrued interest converted to common stock		10,688		11		348,092		—			—			348,103
Net loss								(610,033	)					(610,033	)
Balances, March 31, 2018		264,581	$	265	$	13,380,382	$	(10,258,602	)	$	(1,000,000	)	$	2,122,045
Common stock issued for cash		1,500		2		14,998		—			—			15,000
Notes payable and accrued interest converted to common stock		20,236		20		365,795		—			—			365,815
Common stock issued for services		6,000		6		88,794		—			—			88,800
Net loss								(726,247	)					(726,247	)
Balances, June 30, 2018		292,317	$	293	$	13,849,969	$	(10,984,849	)	$	(1,000,000	)	$	1,865,413
Notes payable and accrued interest converted to common stock		34,371		34		308,875		—			—			308,909
Net loss								(608,519	)					(608,519	)
Balances, September 30, 2018		326,688	$	327	$	14,158,844	$	(11,593,368	)	$	(1,000,000	)	$	1,565,803

Balances, December 31, 2018		429,720	$	430	$	14,695,403	$	(12,462,814	)	$	(1,000,000	)	$	1,233,019
Compensation for vested stock options		—		—		1,025		—			—			1,025
Notes payable and accrued interest converted to common stock		293,455		293		548,515		—			—			548,808
Net loss								(559,397	)					(559,397	)
Balances, March 31, 2019		723,175	$	723	$	15,244,943	$	(13,022,211	)	$	(1,000,000	)	$	1,223,455
Notes payable and accrued interest converted to common stock		71,933		72		355,519		—			—			355,591
Amounts due to related parties converted to common stock		2,000		2		4,998		—			—			5,000
Net loss								(570,365	)					(570,365	)
Balances, June 30, 2019		797,108	$	797	$	15,605,460	$	(13,592,576	)	$	(1,000,000	)	$	1,013,681
Net loss								(373,749	)					(373,749	)
Balances, September 30, 2019		797,108	$	797	$	15,605,460	$	(13,966,325	)	$	(1,000,000	)	$	639,932

See accompanying notes to the condensed consolidated financial statements.

CLINIGENCE HOLDINGS, INC.
(FORMERLY KNOWN AS IGAMBIT INC.)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30,
(UNAUDITED)


		2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,503,511	)	$	(1,944,799	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		742			1,295
Amortization		521,902			521,902
Non cash interest expense		231,563			312,412
Stock-based compensation expense		1,025			88,800
Loss on extinguishment of debt		262,566			233,734
Change in fair value of derivative liability		(98,944	)		128,100
Changes in operating assets and liabilities:
Accounts receivable		4,871			(19,727	)
Inventory		85			—
Prepaid expenses and other current assets		(5,971	)		39,377
Deposits		1,720			—
Accounts payable and accrued expenses		260,195			(68,928	)
Deferred revenue		(8,592	)		(4,933	)
NET CASH USED IN OPERATING ACTIVITIES		(332,349	)		(712,767	)

CASH FLOWS FROM INVESTING ACTIVITIES:		—			—

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures		168,500			676,500
Repayments of convertible debentures		(257,693	)		—
Proceeds from sale of common stock		—			30,000
Proceeds from notes payable		443,093			—
Proceeds from related party loans		11,254			—
Repayments of related party loans		(23,145	)		—
NET CASH PROVIDED BY FINANCING ACTIVITIES		342,009			706,500

NET INCREASE (DECREASE) IN CASH		9,660			(6,267	)
CASH - BEGINNING OF PERIOD		369			9,449
CASH - END OF PERIOD	$	10,029		$	3,182

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	2,752		$	2,563

Non-cash investing and financing activities:
Debt discount related to derivative liability	$	222,500		$	533,249
Notes payable converted to common stock		326,189			387,000
Common stock issued in payment of accrued interest		19,868			23,746

See accompanying notes to the condensed consolidated financial statements.

CLINIGENCE HOLDINGS, INC.

(FORMERLY KNOWN AS IGAMBIT INC.)

Notes to Condensed Consolidated Financial Statements

Nine Months Ended September 30, 2019 and 2018

Note 1 - Organization and Basis of Presentation

The consolidated financial statements presented are those of Clinigence Holdings, Inc., formerly known as iGambit Inc., (the “Company”) and its wholly-owned subsidiary, HealthDatix, Inc. (“HealthDatix”). The name was changed to Clinigence Holdings, Inc. on October 29, 2019. The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States. Clinigence Holdings, Inc. is a healthcare information technology company that provides cloud-based platforms that enable healthcare organizations to shift to value-based care reimbursements and to provide population health management (See Note 16).

Interim Financial Statements

The following (a) condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 16, 2019.

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the nine months ended September 30, 2019 and year ended December 31, 2018.

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the nine months ended September 30, 2019 and 2018.

Clinigence Holdings, Inc. is a holding company and has no sources of revenue.

HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers. HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

Inventory

Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Property and equipment and depreciation

Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

Long-Lived Assets

The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

Deferred Revenue

Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $600 and $9,192 as of September 30, 2019 and December 31, 2018, respectively.

Stock-Based Compensation

The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

Income Taxes

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

Recent Accounting Pronouncements

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 3 – Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $13,966,325, and a working capital deficit of $1,411,857 at September 30, 2019. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments. In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 – Property and Equipment

Property and equipment are carried at cost and consist of the following at September 30, 2019 and December 31, 2018:

	2019		2018
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		9,588		8,846
	$	1,376	$	2,118

Depreciation expense of $742 and $1,295 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Note 5 – Intangible Assets

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at September 30, 2019 and December 31, 2018:

	2019		2018
Software	$	156,925	$	156,925	5 years
Customer contracts		644,846		644,846	10 years
FDA 510K clearance		1,396,000		1,396,000	5 years
Technology license		1,000,000		1,000,000	5 years
In process research and development		604,000		604,000	Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		1,751,658		1,229,756
	$	2,050,113	$	2,572,015

Amortization expense of $521,902 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Note 6 - Earnings (Loss) Per Common Share

The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the nine months ended September 30, 2019 and 2018 as the result would be anti-dilutive.

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Stock options		2,000,000		8,463,000		2,000,000		8,463,000
Stock warrants		1,625,000		1,900,000		1,625,000		1,900,000
Convertible debt		600		410,802		600		410,802
Total shares excluded from calculation		3,625,600		10,773,802		3,625,600		10,773,802

Note 7 – Stock Based Compensation

Options

In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan"). Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of June 30, 2019, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.

The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock. 8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date. There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.

Stock option activity during the nine months ended September 30, 2019 and 2018 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Life (Years)
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at September 30, 2018		8,463,000		$	0.07		0.07		6.66
Options outstanding at December 31, 2018		20,500,000			0.03		0.03		7.52
Options cancelled (1)		(18,250,000	)		0.03		—
Options expired		(250,000	)		0.05		—
Options outstanding at September 30, 2019		2,000,000		$	0.07	$	0.07		6.49

(1) Options to iGambit management and key consultants were cancelled in connection with the reverse stock split prior to the reverse merger agreement consummated on October 29, 2019.

Options outstanding at September 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	March 24, 2015		200,000		200,000	$	0.01		March 24, 2020
	June 6, 2017		1,800,000		1,800,000	$	0.07		June 6, 2027
	Total		2,000,000		2,000,000

Warrants

In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expired on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.

Warrant activity during the nine months ended September 30, 2019 and 2018 follows:

	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2017		400,000		$	0.62	$	0.10		3.27
Warrant granted		1,500,000			0.05		—
Warrants outstanding at September 30, 2018		1,900,000		$	0.21	$	0.12		3.49
Warrants outstanding at December 31, 2018		1,875,000		$	0.12	$	0.12		3.24
Warrants expired		(250,000	)		0.73		—
Warrants outstanding at September 30, 2019		1,625,000		$	0.03	$	0.03		2.90

Warrants outstanding at September 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	January 1, 2017		50,000		50,000	$	0.25		October 10, 2021
	January 1, 2017		50,000		50,000	$	0.50		November 7, 2021
	January 5, 2017		25,000		25,000	$	0.50		January 5, 2022
	February 5, 2018		750,000		750,000	$	0.05		February 5, 2023
	April 27, 2018		750,000		750,000	$	0.05		April 27, 2023
	Total		1,625,000		1,625,000

Note 8 – Convertible Debt

Convertible Notes Payable

On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $240,000, convertible into shares of the Company’s common stock, and includes a back-ended note with principal of $120,000 that was funded on July 10, 2018. The back-ended Note, including accrued interest is due July 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted $71,732 of the principal balance and accrued interest of $5,366 to 97,388 shares of common stock. The principal balance of the note of $94,268, accrued interest of $7,417, and prepayment penalty of $5,000 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date. During the nine months ended September 30, 2019, the noteholder converted the remaining principal balance of $60,000 and accrued interest of $4,342 to 70,893 shares of common stock.

On May 3, 2018, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35% applied to the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 130%. During the nine months ended September 30, 2019, the noteholder converted the remaining principal balance of $53,957 and accrued interest of $4,600 to 51,349 shares of common stock.

On June 25, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted the remaining principal balance of $38,000 and accrued interest of $2,120 to 29,719 shares of common stock.

On August 13, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due May 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $2,120 to 52,495 shares of common stock.

On September 17, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $33,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due June 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $1,320 to 63,525 shares of common stock.

On January 3, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,659, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On February 15, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due November 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,259, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On March 29, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due February 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $810, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

On May 22, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $280, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).

The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 9) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated January 10, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated March 6, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated May 3, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated June 25, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated August 13, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated September 17, 2018 and was amortized through the date the convertible debt was fully extinguished. Interest expense on the convertible notes of $218,454 and $119,603 was recorded for the nine months ended September 30, 2019 and 2018, respectively.

The Company issued convertible debentures in the amount of $75,000 to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the year. Interest expense on the convertible debentures of $5,589 was recorded for the nine months ended September 30, 2019 and 2018, respectively.

Convertible notes payable at September 30, 2019 and December 31, 2018 are summarized as follows:

	2019		2018
Total face value of notes	$	75,000	$	478,957
Less: Discount		2,454		101,346
Balance	$	72,546	$	377,611

Note 9 – Derivative Liability

The Company has determined that the conversion feature embedded in the convertible notes described in Note 8 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception. The Company used the Binomial Option Pricing model to value the conversion features.

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:

	September 30,	December 31,
	2019	2018
Annual dividend yield	—	—
Expected life (years)	0.78 - 1.0	0.77 - 1.0
Risk-free interest rate	2.44% - 2.52%	2.07% - 2.57%
Expected volatility	274% - 294%	257% - 293%

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Note 10 – Notes Payable

On June 24, 2019, the Company entered into a secured promissory note with Clinigence Holdings, Inc. (“Clinigence”) for proceeds of $393,093, of which $293,093 was utilized to pay outstanding principal, accrued interest and penalties of certain convertible notes payable, and $100,000 was utilized for working capital. The note bears interest at a rate of 6% and is due upon the earlier of December 24, 2019 or the Merger Agreement (See note 16). The Company entered into two additional secured promissory notes with Clinigence for proceeds of $25,000 each on August 6, 2019 and September 9, 2019, respectively under the same terms as the June 24, 2019 note.

Notes payable at September 30, 2019 and December 31, 2018 includes loans to HealthDatix from 3 individuals totaling $52,500. The loans do not bear interest and there are no specific terms for repayment.

Note 11 – Stock Transactions

Designation of Preferred Stock

On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company.

Reverse Stock Split

On October 25, 2019, the Company effected a 1-for-500 reverse stock split of its common stock. On the effective date of the reverse stock split, each 500 shares of outstanding common stock were reduced to one share of common stock. The share numbers have been adjusted on a retrospective basis to reflect this 1-for-500 reverse stock split.

Common Stock Issued

On August 8, 2018, the Board unanimously approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock which the Company is authorized to issue from Four hundred million (400,000,000) to Eight Hundred Million (800,000,000) shares of Common Stock, $0.001 par value per share.

In connection with the convertible notes payable (see Note 8 above) the noteholders converted $326,189 of principal balance and $19,868 of accrued interest to 365,388 shares of common stock during the nine months ended September 30, 2019. The stock issued was determined based on the terms of the convertible notes.

Note 12 - Income Taxes

A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 13 – Concentrations and Credit Risk

Sales and Accounts Receivable

HealthDatix had sales to two customers which accounted for approximately 15% and 14%, respectively of HealthDatix’s total sales for the nine months ended September 30, 2019. One customer accounted for 100% of accounts receivable at September 30, 2019.

HealthDatix had sales to two customers which accounted for approximately 66% and 32%, respectively of HealthDatix’s total sales for the nine months ended September 30, 2018. The two customers accounted for approximately 77% and 19%, respectively of accounts receivable at September 30, 2018.

Cash

Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at September 30, 2019 and December 31, 2018, respectively.

Note 14 - Related Party Transactions

Amounts Due to Related Parties

Amounts due to related parties with balances of $128,476 and $145,367 at September 30, 2019 and December 31, 2018, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 15 – Commitments and Contingencies

Lease Commitment

The Company was obligated under an operating lease for its premises in Smithtown, New York that expired on May 31, 2019. The lease was not renewed and the officers of the Company are providing office space to the Company at no charge.

Rent expense of $17,711 and $21,363 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Employment Arrangements With Executive Officers

Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 16 – Subsequent Events

On August 8, 2019, iGambit, Inc. entered into an Agreement and Plan of Merger (the “Reverse Merger Agreement”) by and among Clinigence Holdings, Inc., a Delaware corporation (“Clinigence”), iGambit, Inc., a Delaware corporation (“iGambit” or the “Company”), HealthDatix, Inc., a Delaware corporation and wholly owned subsidiary of iGambit (“Merger Sub”), and John Salerno, an individual and holder of shares of iGambit capital stock constituting a majority of the votes eligible to be cast by all of the stockholders of iGambit (the “Signing Stockholder”). The transactions contemplated by the Reverse Merger Agreement were consummated on October 29, 2019 (the “Closing”).

The Reverse Merger Agreement provided for the merger of Merger Sub with and into Clinigence, hereafter referred to as the “Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and Clinigence became the surviving corporation and a direct wholly owned subsidiary of iGambit, and the former stockholders of Clinigence (the “Clinigence Stockholders”) have a direct equity ownership and controlling interest in iGambit. Merger Sub was renamed Clinigence Health Inc. iGambit was renamed Clinigence Holdings, Inc. Merger Sub was originally incorporated in Delaware on October 17, 2013 and had no operating activity prior to the reported transaction.

At the Closing, all of the outstanding shares of Clinigence common stock (the “Clinigence Shares”) were converted solely into the right to receive a number of shares of iGambit common stock (the “Company Shares”) such that the holders of outstanding equity of Clinigence immediately prior to the Closing own 85%, on a fully-diluted basis, of the outstanding equity of iGambit immediately following the Closing, and holders of outstanding equity of iGambit immediately prior to the Closing own 15%, on a fully-diluted basis, of the outstanding equity of iGambit. For each share of Clinigence Shares, each former Clinigence Stockholder received 0.22489093 shares of Company Shares after giving effect to the reverse stock split.

In connection with the Acquisition, the Company amended its certificate of incorporation to (i) effect a reverse stock split of the Company Shares at a ratio of 1 for 500 (the “Reverse Split Certificate of Amendment”), and (ii) change its name to Clinigence Holdings, Inc. to better align with the business of Clinigence (the “Name Change Certificate of Amendment”).

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

INTRODUCTION

On August 8, 2019, the Company entered into an Agreement and Plan of Merger (the “Reverse Merger Agreement”) by and among Clinigence Holdings, Inc., a Delaware corporation (“Clinigence”), iGambit, Inc., a Delaware corporation (“iGambit” or the “Company”), HealthDatix, Inc., a Delaware corporation and wholly owned subsidiary of iGambit (“Merger Sub”), and John Salerno, an individual and holder of shares of iGambit capital stock constituting a majority of the votes eligible to be cast by all of the stockholders of iGambit (the “Signing Stockholder”). The transactions contemplated by the Reverse Merger Agreement were consummated on October 29, 2019 (the “Closing”).

The Company is focused on the medical technology markets. Our primary focus is the expansion of our subsidiaries HealthDatix Inc. (“HealthDatix”) and our newly acquired subsidiary Clinigence Health Inc. (“Clinigence”).

HealthDatix is an end to end Software-as-a-Service solution that manages, reports, and analyzes critical data, enabling healthcare organizations to deliver positive patient outcomes. HealthDatix provides an opportunity for physicians to identify patients eligible for both “Annual Wellness Visits” (AWV) as well as “Chronic Care Management” both of which are reimbursed by Medicare.

The HealthDatix AWV solution offers a fully-hosted cloud service for healthcare providers to conduct the Medicare Annual Wellness Visit (AWV) program to their Medicare patients providing the patient with a 5-10 year Personalized Preventive Plan and physician reports that meet all Medicare audit requirements. The AWV is a program that allows a physician to identify those patients that have 2+ chronic conditions that require additional screening and management.

Additionally, the HealthDatix Chronic Care Management System (CCM), encompasses our FDA approved Electronic House Call system and Medicare covered platform, for continuous management of chronic care patients. The CCM platform can be tailored for individual care and health management of patients susceptible to chronic illness. The CCM platform is also designed to accumulate information from our BioDatix HealthBand, or any TeleMedicine or wearable device.

The HealthDatix, BioDatix Health Band, provides the ability to passively collect a wearers Heart Rate, Blood Oxygen, Blood Pressure, Sleep and Steps/Distance/Calories.

Clinigence is a healthcare information technology company providing an advanced, cloud-based platform that enables healthcare organizations to provide value-based care and population health management. The Clinigence platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of each patient and provider and virtually unlimited insights into patient populations. Clinigence’s solutions help healthcare organizations improve the quality and cost effectiveness of care, enhance population health management and optimize provider networks.

Assets. At September 30, 2019, we had $2,104,777 in total assets, compared to $2,618,466 at December 31, 2018. The decrease in total assets was primarily due to amortization of intangible assets from the acquisition of our HealthDatix subsidiary.

Liabilities. At September 30, 2019, our total liabilities were $1,464,845 compared to $1,385,447 at December 31, 2018. Our current liabilities at September 30, 2019 consisted of accounts payable and accrued expenses of $740,465, accrued interest on notes payable of $27,165, amounts due to related parties of $128,476, deferred revenue of $600, notes payable of $495,593, and convertible notes payable of $72,546, whereas our current liabilities at December 31, 2018 consisted of accounts payable and accrued expenses of $480,270, accrued interest on notes payable of $32,265 amounts due to related parties of $145,367, deferred revenue of $9,192, notes payable of $52,500, convertible notes payable of $377,611, and derivative liability of $288,242.

Stockholders’ Equity. Our Stockholders’ Equity was $639,932 at September 30, 2019 compared to Stockholders Equity of $1,233,019 at December 31, 2018. This decrease was primarily due to an increase in accumulated deficit during the nine months ended September 30, 2019.

Three Months Ended SEPTEMBER 30, 2019 as Compared to Three Months Ended SEPTEMBER 30, 2018

Revenues and Net Income. We had $7,550 of revenue from our HealthDatix subsidiary and a net loss of $373,749 during the three months ended September 30, 2019, compared to revenue of $22,582 and a net loss of $608,519 for the three months ended September 30, 2018. The decrease in revenue was due primarily to revenue generated by our HealthDatix subsidiary.

General and Administrative Expenses. General and Administrative Expenses decreased to $187,295 for the three months ended September 30, 2019 from $207,793 for the three months ended September 30, 2018. For the three months ended September 30, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $23,232, legal and accounting fees of $45,621, employee benefits expenses (health and life insurance) of $2,269, payroll expenses of $98,245, exchange filing fees of $4,081 transfer agent expense of $1,398, rent expense of $2,449, and contract labor expense of $10,000. For the three months ended September 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $28,588, legal and accounting fees of $29,798, employee benefits expenses (health and life insurance) of $7,683, marketing expenses of $6,153, payroll expenses of $89,725, exchange filing fees of $8,897, transfer agent expense of $6,600, rent expense of $7,128, contract labor expense of $10,440, finders fees expense of $5,000, errors and omissions insurance expense of $5,281, and trade show expense of $2,500. The decreases from the three months ended September 30, 2018 to the three months ended September 30, 2019 relate primarily due to: (i) a decrease in employee benefits, (ii) a decrease in marketing expenses; and (iii) a decrease in consulting and commissions expenses. Costs associated with the operations of our HealthDatix and Clinigence subsidiaries are expected to increase going forward, as we expand the business operations of Clinigence and HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported interest expense of $9,995 for the three months ended September 30, 2019. We reported income from a change in fair value of derivative liability of $76,091, loss on extinguishment of debt of $95,464 and interest expense of $222,134 for the three months ended September 30, 2018.

NINE Months Ended SEPTEMBER 30, 2019 as Compared to NINE Months Ended SEPTEMBER 30, 2018

Revenues and Net Income (Loss). We had $19,175 of revenue from our HealthDatix subsidiary and a net loss of $1,503,511 during the nine months ended September 30, 2019, compared to $30,500 of revenue from our HealthDatix subsidiary and net income of $1,944,799, for the nine months ended September 30, 2018. The increase in revenue was due primarily to the revenue generated by our HealthDatix subsidiary.

General and Administrative Expenses. General and Administrative Expenses decreased to $576,512 for the nine months ended September 30, 2019 from $752,930 for the nine months ended September 30, 2018. For the nine months ended September 30, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $106,277, legal and accounting fees of $85,862, employee benefits expenses (health and life insurance) of $8,468, payroll expenses of $304,346, filing fees expense of $5,690, rent expense of $17,712, transfer agent expense of $18,940, contract labor expense of $24,500, and consulting fees expense of $4,717. For the nine months ended September 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $32,359, legal and accounting fees of $74,378, employee benefits expenses (health and life insurance) of $28,591, marketing expenses of $49,769, payroll expenses of $298,155, exchange filing fees expense of $19,707, rent expense of $21,363, transfer agent expense of $24,475, contract labor expense of $34,640, consulting fees expense of $89,400, finders fees of $26,000, errors and omissions insurance expense of $5,281, marketing expense of $40,769, and trade show expense of $8,043. The decreases from the nine months ended September 30, 2019 to the nine months ended September 30, 2018 relate primarily due to: (i) a decrease in employee benefits, (ii) a decrease in marketing expenses; (iii) a decrease in filing fees expenses, and (iv) a decrease in consulting and fees expenses. Costs associated with the operations of our HealthDatix and Clinigence subsidiaries are expected to increase going forward, as we expand the business operations of Clinigence and HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported income from a change in fair value of derivative liability of $98,944, loss on extinguishment of debt of $262,566 and interest expense of $234,314 for the nine months ended September 30, 2019. We reported expense from a change in fair value of derivative liability of $(128,100), loss on extinguishment of debt of $233,734 and interest expense of $314,975 for the nine months ended September 30, 2018.

Liquidity and Capital Resources AND ABILITY TO CONTINUE AS A GOING CONCERN

General

As reflected in the accompanying consolidated financial statements, at September 30, 2019, we had $10,029 of cash and stockholders’ equity of $639,932. At December 31, 2018, we had $369 of cash and stockholders’ equity of $1,233,019.

Our primary capital requirements in 2019 are likely to arise from the expansion of our HealthDatix and Clinigence operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s and Clinigence’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s and Clinigence’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

Cash Flow Activity

Net cash used in operating activities was $332,349, for the nine months ended September 30, 2019, compared to $712,767 for the nine months ended September 30, 2018. Our primary use of operating cash flows from operating activities was from net losses of $1,503,511 and $1,944,799 for the nine months ended September 30, 2019 and 2018, respectively. Additional contributing factors to the change were from depreciation expense of $742, amortization expense of $521,902, non-cash interest expense of $231,563, stock based compensation of $1,025, loss on the extinguishment of debt of $262,566, a change in fair value of derivative liability of $98,944, decrease in accounts receivable of $4,871, a decrease in inventory of $85, an increase in prepaid expenses of $5,971, a decrease in deposits of $1,720, an increase in accounts payable and accrued expenses of $260,195, and a decrease in deferred revenue of $8,592.

There was no cash used in investing activities for the nine months ended September 30, 2019 and 2018, respectively.

Net Cash provided by financing activities was $342,009 for the nine months ended September 30, 2019 compared to $706,500 for the nine months ended September 30, 2018. The cash flows provided by financing activities for the nine months ended September 30, 2019 was primarily from $443,093 in proceeds from notes payable.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not Required.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended September 30, 2019.

Item 1A. Risk Factors.

Not required

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults upon Senior Securities.

None

Item 4. Removed and Reserved.

Item 5. Other Information.

None

Item 6. Exhibits

Exhibit No.	Description
31.1	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
32.2	Certification of the Interim Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 19, 2019.

	Clinigence Holdings, Inc.

	/s/ John Salerno
	John Salerno
	Chief Executive Officer



	/s/ Elisa Luqman
	Elisa Luqman
	Chief Financial Officer

Exhibit Index

Exhibit No.	Description
31.1	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
32.2	Certification of the Interim Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

I, John Salerno, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Clinigence Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 19, 2019			/s/ John Salerno
			Chief Executive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

I, Elisa Luqman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Clinigence Holdings, Inc..;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 19, 2019			/s/ Elisa Luqman
			Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

WRITTEN STATEMENT OF THE CHIEF EXECUTIVE OFFICER
Pursuant to 18 U.S.C. Section 1350
As adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002

Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Executive Officer of Clinigence Holdings, Inc.. (the “Company”), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2019, (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 19, 2019			/s/ John Salerno
			Chief Executive Officer

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

WRITTEN STATEMENT OF THE CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. Section 1350
As adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002

Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Financial Officer of Clinigence Holdings, Inc.. (the “Company”), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2019, (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 19, 2019			/s/ Elisa Luqman
			Chief Financial Officer

EX-101.INS 6 igmb-20190930.xml XBRL INSTANCE FILE 0001479681 2019-09-30 0001479681 2018-12-31 0001479681 2019-01-01 2019-09-30 0001479681 2018-01-01 2018-09-30 0001479681 igmb:OfficeEquipmentAndFixturesMember srt:MinimumMember 2019-01-01 2019-09-30 0001479681 igmb:OfficeEquipmentAndFixturesMember srt:MaximumMember 2019-01-01 2019-09-30 0001479681 igmb:ComputerHardwareMember 2019-01-01 2019-09-30 0001479681 igmb:ComputerSoftwareMember 2019-01-01 2019-09-30 0001479681 igmb:DevelopmentEquipmentMember 2019-01-01 2019-09-30 0001479681 igmb:SoftwareMember 2019-01-01 2019-09-30 0001479681 igmb:TechnologylicenseMember 2019-01-01 2019-09-30 0001479681 us-gaap:CustomerContractsMember 2019-01-01 2019-09-30 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-09-30 0001479681 igmb:SoftwareMember 2019-09-30 0001479681 us-gaap:CustomerContractsMember 2019-09-30 0001479681 igmb:FDA510KClearanceMember 2019-09-30 0001479681 igmb:TechnologylicenseMember 2019-09-30 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0001479681 igmb:FDA510KClearanceMember 2019-01-01 2019-09-30 0001479681 igmb:SoftwareMember 2018-12-31 0001479681 us-gaap:CustomerContractsMember 2018-12-31 0001479681 igmb:FDA510KClearanceMember 2018-12-31 0001479681 igmb:TechnologylicenseMember 2018-12-31 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001479681 us-gaap:StockOptionMember 2019-01-01 2019-09-30 0001479681 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001479681 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001479681 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001479681 igmb:Options1Member 2019-01-01 2019-09-30 0001479681 igmb:Options2Member 2019-01-01 2019-09-30 0001479681 igmb:Options1Member 2019-09-30 0001479681 igmb:Options2Member 2019-09-30 0001479681 igmb:Warrants1Member 2019-01-01 2019-09-30 0001479681 igmb:Warrants2Member 2019-01-01 2019-09-30 0001479681 igmb:Warrants3Member 2019-01-01 2019-09-30 0001479681 igmb:Warrants4Member 2019-01-01 2019-09-30 0001479681 igmb:Warrants5Member 2019-01-01 2019-09-30 0001479681 igmb:Warrants1Member 2019-09-30 0001479681 igmb:Warrants2Member 2019-09-30 0001479681 igmb:Warrants3Member 2019-09-30 0001479681 igmb:Warrants4Member 2019-09-30 0001479681 igmb:Warrants5Member 2019-09-30 0001479681 srt:MinimumMember 2019-01-01 2019-09-30 0001479681 srt:MaximumMember 2019-01-01 2019-09-30 0001479681 srt:MinimumMember 2018-01-01 2018-09-30 0001479681 srt:MaximumMember 2018-01-01 2018-09-30 0001479681 igmb:NoteholderMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:NoteholderMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:NoteholderMember 2019-01-01 2019-09-30 0001479681 us-gaap:SalesMember igmb:FirstCustomersMember 2019-01-01 2019-09-30 0001479681 us-gaap:SalesMember igmb:SecondCustomersMember 2019-01-01 2019-09-30 0001479681 us-gaap:AccountsReceivableMember igmb:OneCustomerMember 2019-01-01 2019-09-30 0001479681 us-gaap:SalesMember igmb:FirstCustomersMember 2018-01-01 2018-09-30 0001479681 us-gaap:SalesMember igmb:SecondCustomersMember 2018-01-01 2018-09-30 0001479681 us-gaap:AccountsReceivableMember igmb:OneCustomerMember 2018-01-01 2018-09-30 0001479681 2018-09-30 0001479681 2017-12-31 0001479681 igmb:ConvertibleNoteOneMember igmb:PrincipalMember 2017-03-01 2017-03-30 0001479681 igmb:ConvertibleNoteFiveMember igmb:PrincipalMember 2018-01-01 2018-01-10 0001479681 igmb:ConvertibleNoteFiveMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteFiveMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteFiveMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteSevenMember igmb:PrincipalMember 2018-03-01 2018-03-06 0001479681 igmb:ConvertibleNoteSevenMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteSevenMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteSevenMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteEightMember igmb:PrincipalMember 2018-05-01 2018-05-03 0001479681 igmb:ConvertibleNoteEightMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteEightMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteEightMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteNineMember igmb:PrincipalMember 2018-06-01 2018-06-25 0001479681 igmb:ConvertibleNoteNineMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteNineMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteNineMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteTenMember igmb:PrincipalMember 2018-08-01 2018-08-13 0001479681 igmb:ConvertibleNoteTenMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteTenMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteTenMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteElevenMember igmb:PrincipalMember 2018-09-01 2018-09-17 0001479681 igmb:ConvertibleNoteTwelveMember 2019-01-01 2019-01-03 0001479681 igmb:ConvertibleNoteThirteenMember 2019-02-01 2019-02-15 0001479681 igmb:ConvertibleNoteFourteenMember 2019-03-01 2019-03-29 0001479681 2019-11-19 0001479681 us-gaap:StockOptionMember 2019-07-01 2019-09-30 0001479681 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001479681 2019-07-01 2019-09-30 0001479681 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001479681 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001479681 2018-07-01 2018-09-30 0001479681 igmb:ConvertibleNoteFiveMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteElevenMember igmb:PrincipalMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteElevenMember igmb:AccruedInterestMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteElevenMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleNoteTwelveMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteThirteenMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteFourteenMember 2019-06-01 2019-06-24 0001479681 igmb:ConvertibleNoteFifteenMember 2019-03-01 2019-03-29 0001479681 igmb:ConvertibleNoteFifteenMember 2019-06-01 2019-06-24 0001479681 igmb:ClinigenceHoldingsMember 2019-08-01 2019-08-08 0001479681 2018-01-01 2018-12-31 0001479681 us-gaap:AccountsReceivableMember igmb:SecondCustomersMember 2018-01-01 2018-09-30 0001479681 2019-10-01 2019-10-25 0001479681 igmb:SecuredPromissoryNotesMember 2019-06-01 2019-06-24 0001479681 igmb:SecuredPromissoryNotesMember 2019-08-01 2019-08-06 0001479681 igmb:SecuredPromissoryNotesMember 2019-09-01 2019-09-09 0001479681 igmb:ConvertibleDebtsMember 2019-07-01 2019-09-30 0001479681 igmb:ConvertibleDebtsMember 2018-07-01 2018-09-30 0001479681 igmb:ConvertibleDebtsMember 2019-01-01 2019-09-30 0001479681 igmb:ConvertibleDebtsMember 2018-01-01 2018-09-30 0001479681 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001479681 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001479681 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001479681 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001479681 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001479681 us-gaap:CommonStockMember 2018-12-31 0001479681 us-gaap:CommonStockMember 2019-03-31 0001479681 us-gaap:CommonStockMember 2019-06-30 0001479681 us-gaap:CommonStockMember 2019-09-30 0001479681 us-gaap:CommonStockMember 2017-12-31 0001479681 us-gaap:CommonStockMember 2018-03-31 0001479681 us-gaap:CommonStockMember 2018-06-30 0001479681 us-gaap:CommonStockMember 2018-09-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001479681 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001479681 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001479681 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001479681 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001479681 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001479681 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001479681 us-gaap:RetainedEarningsMember 2018-12-31 0001479681 us-gaap:RetainedEarningsMember 2019-03-31 0001479681 us-gaap:RetainedEarningsMember 2019-06-30 0001479681 us-gaap:RetainedEarningsMember 2019-09-30 0001479681 us-gaap:RetainedEarningsMember 2017-12-31 0001479681 us-gaap:RetainedEarningsMember 2018-03-31 0001479681 us-gaap:RetainedEarningsMember 2018-06-30 0001479681 us-gaap:RetainedEarningsMember 2018-09-30 0001479681 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001479681 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001479681 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001479681 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001479681 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001479681 us-gaap:TreasuryStockMember 2018-12-31 0001479681 us-gaap:TreasuryStockMember 2019-03-31 0001479681 us-gaap:TreasuryStockMember 2019-06-30 0001479681 us-gaap:TreasuryStockMember 2019-09-30 0001479681 us-gaap:TreasuryStockMember 2017-12-31 0001479681 us-gaap:TreasuryStockMember 2018-03-31 0001479681 us-gaap:TreasuryStockMember 2018-06-30 0001479681 us-gaap:TreasuryStockMember 2018-09-30 0001479681 2019-01-01 2019-03-31 0001479681 2019-04-01 2019-06-30 0001479681 2018-01-01 2018-03-31 0001479681 2018-04-01 2018-06-30 0001479681 2019-03-31 0001479681 2019-06-30 0001479681 2018-03-31 0001479681 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q 2019-09-30 false Clinigence Holdings, Inc. 0001479681 --12-31 Non-accelerated Filer 2019 Q3

.001

100000000

800000000

10000000

Yes false true

P5Y

P7Y

P5Y

P3Y

P5Y

P10Y

P5Y

Indefinite

329

600

9192

-1411857

10964

9588

8846

3801771

156925

644846

1396000

1000000

604000

156925

644846

1396000

1000000

604000

1751658

1229756

2050113

2572015

521902

3625600

10773802

2000000

1625000

8463000

1900000

2000000

1625000

3625600

8463000

1900000

10773802

600

410802

600

410802

2000000

20500000

200000

1800000

8463000

0.07

0.03

0.01

0.07

0.03

0.07

P7Y6M7D

P7Y4M28D

P6Y5M27D P6Y7M28D 2015-03-24 2017-06-06

2000000

200000

1800000

2020-03-24 2027-06-06

1625000

1875000

1900000

400000

0.03 0.12 0.21 0.62

0.03

0.12

0.10

P3Y2M27D

P3Y3M8D

P2Y10M25D P3Y5M27D

2017-01-01

2017-01-05

2018-02-05

2018-04-27

1625000

50000

25000

750000

1625000

50000

25000

750000

0.25

0.50

0.05

75000

478957

2454

101346

326189

19868

75000

240000

71732

5366

126000

60000

4342

83500

53957

4600

53000

38000

2120

53000

2120

33000

38000

33000

1320

38000

365388

97388

70893

51349

29719

52495

63525

0.00

P9M11D

P1Y

P9M7D

P1Y

0.0244

0.0252

0.0207

0.0257

2.74

2.94

2.57

2.93

0.15

0.14

1.00

0.66

0.32

0.77

0.19

250000

128476

145367

17711

21363

P3Y

75000

4627721 2021-10-10 2021-11-07 2022-01-05 2023-02-05 2023-04-27

218454

119603

5589 5589

0.08

2018-06-25

2018-07-10

2019-03-06

2019-05-03

2019-04-15

2019-05-30

2019-06-30

2019-10-30

2019-11-30

2020-02-15

2020-03-15

639932

1233019

1565803

2368975

430

723

797

252

265

293

327

14695403

15244943

15605460

13017292

13380382

13849969

14158844

-12462814

-13022211

-13592576

-13966325

-9648569

-10258602

-10984849

-11593368

-1000000

1223455

1013681

2122045

1865413

false 000-55462

288242

66059

-482211 -928773 292913 1122211

250000

0.05

1500000

0.05 -250000 0.73

94268

38000

7417 1659 1259 810 810 5000 7600 7600 7600 7600

443093

393093

25000

797108

429720

777108

409720

98944

-128100

76091

Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Convertible Instruments   The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Cash and Cash Equivalents   For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable   The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly.  A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.  The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

Inventory   Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Long-Lived Assets   The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

Stock-Based Compensation   The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

Income Taxes   The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.   The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

Recent Accounting Pronouncements   We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

1 for 500

1-for-500

52500

0.06

18250000

0.03

52988

42313

5971

26988

27073

10000

14871

10029

369

3182

9449

2104777

2618466

300

2020

2050113

2572015

1376

2118

1464845

1385447

288242

72546

377611

495593

52500

600

9192

128476

145367

27165

32265

740465

480270

2104777

2618466

1000000

1639932 2233019

-13966325

-12462814

15605460

14695403

797

430

false

-7161

6842

-2492

14748

26336

23658

10042

7834

19175

30500

7550

22582

1098414

1274832

361262

381760

521902

173967

576512

752930

187295

207793

-1105575

-1267990

-363754

-367012

-262566

-233734

-95464

234314

314975

9995

222134

-397936

-676809

-9995

-241507

-1503511

-1944799

-373749

-608519

-2.13

-7.39

-.48

-2.09

704331

263269

777108

291514

14998

15000

308909 293 72 11 20 34 548515 355519 348092 365795 308875 548808 355591 348103 365815

-373749

-608519

-559397

-570365

-373749

-610033

-726247

-608519

-559397

-570365

-610033

-726247

88794

88800

429720

723175

797108

252393

264581

292317

326688

293455 71933 10688 20236 34371

6000

1500

1025

2 4998 5000 2000

-332349

-712767

-8592

-4933

-260195

68928

1720

-5971

39377

4871

-19727

1025

88800

231563

312412

742

1295

342009

706500

23145

11254

30000

257693

168500

676500

9660

-6267

2752

2563

19868 23746 326189 387000

222500

533249

Note 16 – Subsequent Events   On August 8, 2019, iGambit, Inc. entered into an Agreement and Plan of Merger (the “Reverse Merger Agreement”) by and among Clinigence Holdings, Inc., a Delaware corporation (“Clinigence”), iGambit, Inc., a Delaware corporation (“iGambit” or the “Company”), HealthDatix, Inc., a Delaware corporation and wholly owned subsidiary of iGambit (“Merger Sub”), and John Salerno, an individual and holder of shares of iGambit capital stock constituting a majority of the votes eligible to be cast by all of the stockholders of iGambit (the “Signing Stockholder”). The transactions contemplated by the Reverse Merger Agreement were consummated on October 29, 2019 (the “Closing”).   The Reverse Merger Agreement provided for the merger of Merger Sub with and into Clinigence, hereafter referred to as the “Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and Clinigence became the surviving corporation and a direct wholly owned subsidiary of iGambit, and the former stockholders of Clinigence (the “Clinigence Stockholders”) have a direct equity ownership and controlling interest in iGambit. Merger Sub was renamed Clinigence Health Inc. iGambit was renamed Clinigence Holdings, Inc. Merger Sub was originally incorporated in Delaware on October 17, 2013 and had no operating activity prior to the reported transaction.   At the Closing, all of the outstanding shares of Clinigence common stock (the “Clinigence Shares”) were converted solely into the right to receive a number of shares of iGambit common stock (the “Company Shares”) such that the holders of outstanding equity of Clinigence immediately prior to the Closing own 85%, on a fully-diluted basis, of the outstanding equity of iGambit immediately following the Closing, and holders of outstanding equity of iGambit immediately prior to the Closing own 15%, on a fully-diluted basis, of the outstanding equity of iGambit. For each share of Clinigence Shares, each former Clinigence Stockholder received 0.22489093 shares of Company Shares after giving effect to the reverse stock split.   In connection with the Acquisition, the Company amended its certificate of incorporation to (i) effect a reverse stock split of the Company Shares at a ratio of 1 for 500 (the “Reverse Split Certificate of Amendment”), and (ii) change its name to Clinigence Holdings, Inc. to better align with the business of Clinigence (the “Name Change Certificate of Amendment”).

Note 15 – Commitments and Contingencies   Lease Commitment   The Company was obligated under an operating lease for its premises in Smithtown, New York that expired on May 31, 2019. The lease was not renewed and the officers of the Company are providing office space to the Company at no charge.   Rent expense of $17,711 and $21,363 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.   Employment Arrangements With Executive Officers   Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 14 - Related Party Transactions   Amounts Due to Related Parties   Amounts due to related parties with balances of $128,476 and $145,367 at September 30, 2019 and December 31, 2018, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 13 – Concentrations and Credit Risk   Sales and Accounts Receivable   HealthDatix had sales to two customers which accounted for approximately 15% and 14%, respectively of HealthDatix’s total sales for the nine months ended September 30, 2019. One customer accounted for 100% of accounts receivable at September 30, 2019.   HealthDatix had sales to two customers which accounted for approximately 66% and 32%, respectively of HealthDatix’s total sales for the nine months ended September 30, 2018. The two customers accounted for approximately 77% and 19%, respectively of accounts receivable at September 30, 2018.   Cash   Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at September 30, 2019 and December 31, 2018, respectively.

Note 12 - Income Taxes   A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 11 – Stock Transactions   Designation of Preferred Stock   On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company.   Reverse Stock Split   On October 25, 2019, the Company effected a 1-for-500 reverse stock split of its common stock. On the effective date of the reverse stock split, each 500 shares of outstanding common stock were reduced to one share of common stock. The share numbers have been adjusted on a retrospective basis to reflect this 1-for-500 reverse stock split.   Common Stock Issued   On August 8, 2018, the Board unanimously approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock which the Company is authorized to issue from Four hundred million (400,000,000) to Eight Hundred Million (800,000,000) shares of Common Stock, $0.001 par value per share.   In connection with the convertible notes payable (see Note 8 above) the noteholders converted $326,189 of principal balance and $19,868 of accrued interest to 365,388 shares of common stock during the nine months ended September 30, 2019. The stock issued was determined based on the terms of the convertible notes.

Note 10 – Notes Payable   On June 24, 2019, the Company entered into a secured promissory note with Clinigence Holdings, Inc. (“Clinigence”) for proceeds of $393,093, of which $293,093 was utilized to pay outstanding principal, accrued interest and penalties of certain convertible notes payable, and $100,000 was utilized for working capital. The note bears interest at a rate of 6% and is due upon the earlier of December 24, 2019 or the Merger Agreement (See note 16). The Company entered into two additional secured promissory notes with Clinigence for proceeds of $25,000 each on August 6, 2019 and September 9, 2019, respectively under the same terms as the June 24, 2019 note.   Notes payable at September 30, 2019 and December 31, 2018 includes loans to HealthDatix from 3 individuals totaling $52,500. The loans do not bear interest and there are no specific terms for repayment.

Note 9 – Derivative Liability   The Company has determined that the conversion feature embedded in the convertible notes described in Note 8 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception. The Company used the Binomial Option Pricing model to value the conversion features.   The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">   September 30,</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">December 31,</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"> </td><td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">2019</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"> </td><td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">2018</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 56%; text-align: left; padding-left: 0pt">Annual dividend yield</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.78 - 1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.77 - 1.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-left: 0pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.44% - 2.52%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.07% - 2.57%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 274% - 294%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 257% - 293%</td><td style="text-align: left"> </td></tr> </table>   Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Note 8 – Convertible Debt   Convertible Notes Payable   On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $240,000, convertible into shares of the Company’s common stock, and includes a back-ended note with principal of $120,000 that was funded on July 10, 2018. The back-ended Note, including accrued interest is due July 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted $71,732 of the principal balance and accrued interest of $5,366 to 97,388 shares of common stock. The principal balance of the note of $94,268, accrued interest of $7,417, and prepayment penalty of $5,000 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date. During the nine months ended September 30, 2019, the noteholder converted the remaining principal balance of $60,000 and accrued interest of $4,342 to 70,893 shares of common stock.   On May 3, 2018, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35% applied to the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 130%. During the nine months ended September 30, 2019, the noteholder converted the remaining principal balance of $53,957 and accrued interest of $4,600 to 51,349 shares of common stock.   On June 25, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted the remaining principal balance of $38,000 and accrued interest of $2,120 to 29,719 shares of common stock.   On August 13, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due May 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $2,120 to 52,495 shares of common stock.   On September 17, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $33,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due June 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the noteholder converted the principal balance of the note and accrued interest of $1,320 to 63,525 shares of common stock.   On January 3, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,659, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On February 15, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due November 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $1,259, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On March 29, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due February 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $810, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   On May 22, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The principal balance of the note of $38,000, accrued interest of $280, and prepayment penalty of $7,600 were paid on June 24, 2019 with proceeds from the Clinigence note (See note 10 below).   The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 9) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated January 10, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated March 6, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated May 3, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated June 25, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated August 13, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated September 17, 2018 and was amortized through the date the convertible debt was fully extinguished. Interest expense on the convertible notes of $218,454 and $119,603 was recorded for the nine months ended September 30, 2019 and 2018, respectively.   The Company issued convertible debentures in the amount of $75,000 to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the year. Interest expense on the convertible debentures of $5,589 was recorded for the nine months ended September 30, 2019 and 2018, respectively.   Convertible notes payable at September 30, 2019 and December 31, 2018 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 56%; padding-left: 0pt">Total face value of notes</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">478,957</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less: Discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,454</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">101,346</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">377,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Note 7 – Stock Based Compensation   Options   In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan").   Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of June 30, 2019, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.   The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock.  8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date.  There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.   Stock option activity during the nine months ended September 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Options Outstanding</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Grant-Date         Fair Value</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Remaining Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 40%; padding-left: 0pt">Options outstanding at December 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">7.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">No option activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Options outstanding at  September 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,463,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Options outstanding at  December 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-left: 0pt">Options cancelled (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,250,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Options outstanding at  September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   (1) Options to iGambit management and key consultants were cancelled in connection with the reverse stock split prior to the reverse merger agreement consummated on October 29, 2019.   Options outstanding at September 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; vertical-align: bottom">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center; vertical-align: bottom">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Date</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 16%; text-align: center; vertical-align: bottom">March 24, 2015</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 15%; text-align: center; vertical-align: bottom">March 24, 2020</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">June 6, 2017</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">June 6, 2027</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td></tr> </table>   Warrants   In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expired on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.   Warrant activity during the nine months ended September 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Warrants Outstanding</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Grant-Date Fair Value</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 40%; padding-left: 0pt">Warrants outstanding at December 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3.27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Warrant granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Warrants outstanding at September 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,900,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right">0.21</td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Warrants outstanding at December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,000</td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left">$</td><td style="font-size: 12pt; text-align: right">0.12</td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Warrants outstanding at September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Warrants outstanding at September 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; vertical-align: bottom">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center; vertical-align: bottom">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Date</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 16%; text-align: center; vertical-align: bottom">January 1, 2017</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 15%; text-align: center; vertical-align: bottom">October 10, 2021</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">January 1, 2017</td><td style="text-align: center; vertical-align: bottom"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">November 7, 2021</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">January 5, 2017</td><td style="text-align: center; vertical-align: bottom"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">January 5, 2022</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">February 5, 2018</td><td style="text-align: center; vertical-align: bottom"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">February 5, 2023</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">April 27, 2018</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">April 27, 2023</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">  Total</td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td></tr></table>

Note 6 - Earnings (Loss) Per Common Share   The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the nine months ended September 30, 2019 and 2018 as the result would be anti-dilutive.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td><td> </td> <td colspan="7" style="text-align: center">Nine Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">September 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 40%; text-align: left; padding-left: 0pt">Stock options</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Stock warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,900,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">410,802</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">410,802</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,625,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,773,802</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,625,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,773,802</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Note 5 – Intangible Assets   Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at September 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 46%; padding-left: 0pt">Software</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-left: 0pt">FDA 510K clearance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">In process research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">Indefinite</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,751,658</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,229,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,050,113</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,572,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Amortization expense of $521,902 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Note 4 – Property and Equipment   Property and equipment are carried at cost and consist of the following at September 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 56%; text-align: left; padding-left: 0pt">Office equipment and fixtures</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,588</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,846</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,376</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Depreciation expense of $742 and $1,295 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Note 3 – Going Concern   The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The Company has an accumulated deficit of $13,966,325, and a working capital deficit of $1,411,857 at September 30, 2019. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time.  The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments.  In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.   The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 – Summary of Significant Accounting Policies   Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  All intercompany accounts and transactions have been eliminated.   Use of Estimates in the Preparation of Financial Statements   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.   Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the nine months ended September 30, 2019 and year ended December 31, 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td>Liabilities:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; padding-left: 0pt">Balance of derivative liabilities - beginning of period</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">288,242</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,059</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-left: 0pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Converted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(482,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(928,773</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(98,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,745</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance of derivative liabilities - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Convertible Instruments   The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.   Revenue Recognition   Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the nine months ended September 30, 2019 and 2018.   Clinigence Holdings, Inc. is a holding company and has no sources of revenue.   HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers.  HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.   Advertising Costs   The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the nine months ended September 30, 2019 and 2018, respectively.   Cash and Cash Equivalents   For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.   Accounts Receivable   The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly.  A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.  The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.   Inventory   Inventory consisting of finished products is stated at the lower of cost or net realizable value. Property and equipment and depreciation   Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; width: 45%">Office equipment and fixtures</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 43%; text-align: right">5 - 7 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Computer hardware</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Computer software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Development equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> </table>   Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; width: 45%">Software</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 43%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Purchased in process R&D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">Indefinite</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> </table>   Long-Lived Assets   The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.   Deferred Revenue   Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $600 and $9,192 as of September 30, 2019 and December 31, 2018, respectively.   Stock-Based Compensation   The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.   Income Taxes   The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.   The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.   Recent Accounting Pronouncements   We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 1 - Organization and Basis of Presentation   The consolidated financial statements presented are those of Clinigence Holdings, Inc., formerly known as iGambit Inc., (the “Company”) and its wholly-owned subsidiary, HealthDatix, Inc. (“HealthDatix”). The name was changed to Clinigence Holdings, Inc. on October 29, 2019. The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States. Clinigence Holdings, Inc. is a healthcare information technology company that provides cloud-based platforms that enable healthcare organizations to shift to value-based care reimbursements and to provide population health management (See Note 16).   Interim Financial Statements   The following (a) condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 16, 2019.

Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the nine months ended September 30, 2019 and year ended December 31, 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td>Liabilities:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; padding-left: 0pt">Balance of derivative liabilities - beginning of period</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">288,242</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,059</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-left: 0pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Converted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(482,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(928,773</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(98,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,745</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance of derivative liabilities - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Revenue Recognition   Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the nine months ended September 30, 2019 and 2018.   Clinigence Holdings, Inc. is a holding company and has no sources of revenue.   HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers.  HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.

Advertising Costs   The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Property and equipment and depreciation   Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; width: 45%">Office equipment and fixtures</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 43%; text-align: right">5 - 7 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Computer hardware</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Computer software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Development equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr></table>

Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; width: 45%">Software</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 43%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Purchased in process R&D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">Indefinite</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr></table> Deferred Revenue   Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $600 and $9,192 as of September 30, 2019 and December 31, 2018, respectively.

The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the nine months ended September 30, 2019 and year ended December 31, 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td>Liabilities:</td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; padding-left: 0pt">Balance of derivative liabilities - beginning of period</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">288,242</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,059</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-left: 0pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Converted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(482,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(928,773</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(98,944</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,745</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance of derivative liabilities - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; width: 45%">Office equipment and fixtures</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 43%; text-align: right">5 - 7 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Computer hardware</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Computer software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Development equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr></table> Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; width: 45%">Software</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 43%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Purchased in process R&D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">Indefinite</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr></table>

Property and equipment are carried at cost and consist of the following at September 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 56%; text-align: left; padding-left: 0pt">Office equipment and fixtures</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,964</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,588</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,846</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,376</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at September 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 46%; padding-left: 0pt">Software</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">156,925</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">5 years</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Customer contracts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,846</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-left: 0pt">FDA 510K clearance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,396,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Technology license</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">In process research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">604,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">Indefinite</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less: Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,751,658</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,229,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,050,113</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,572,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the nine months ended September 30, 2019 and 2018 as the result would be anti-dilutive.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td><td> </td> <td colspan="7" style="text-align: center">Nine Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">September 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 40%; text-align: left; padding-left: 0pt">Stock options</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Stock warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,900,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">410,802</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">410,802</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total shares excluded from calculation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,625,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,773,802</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,625,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,773,802</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Stock option activity during the nine months ended September 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Options Outstanding</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Grant-Date         Fair Value</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Remaining Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 40%; padding-left: 0pt">Options outstanding at December 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">8,463,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">7.41</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">No option activity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Options outstanding at  September 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,463,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Options outstanding at  December 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">20,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-left: 0pt">Options cancelled (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,250,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Options outstanding at  September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Options outstanding at September 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; vertical-align: bottom">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center; vertical-align: bottom">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Date</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 16%; text-align: center; vertical-align: bottom">March 24, 2015</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 15%; text-align: center; vertical-align: bottom">March 24, 2020</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">June 6, 2017</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">June 6, 2027</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td></tr></table>

Warrant activity during the nine months ended September 30, 2019 and 2018 follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Warrants Outstanding</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Weighted Average Grant-Date Fair Value</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 40%; padding-left: 0pt">Warrants outstanding at December 31, 2017</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3.27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Warrant granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Warrants outstanding at September 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,900,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right">0.21</td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Warrants outstanding at December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,875,000</td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left">$</td><td style="font-size: 12pt; text-align: right">0.12</td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Warrants outstanding at September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 12pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Warrants outstanding at September 30, 2019 consist of:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; vertical-align: bottom">Date</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Number</td><td> </td> <td colspan="3" style="text-align: center">Exercise</td><td> </td> <td colspan="3" style="text-align: center; vertical-align: bottom">Expiration</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Issued</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom">Date</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 16%; text-align: center; vertical-align: bottom">January 1, 2017</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: center; vertical-align: bottom"> </td><td style="width: 15%; text-align: center; vertical-align: bottom">October 10, 2021</td><td style="width: 1%; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">January 1, 2017</td><td style="text-align: center; vertical-align: bottom"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">November 7, 2021</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">January 5, 2017</td><td style="text-align: center; vertical-align: bottom"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">January 5, 2022</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">February 5, 2018</td><td style="text-align: center; vertical-align: bottom"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">February 5, 2023</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">April 27, 2018</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">April 27, 2023</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">  Total</td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,625,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 2.5pt; text-align: center; vertical-align: bottom"> </td></tr></table>

Convertible notes payable at September 30, 2019 and December 31, 2018 are summarized as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 56%; padding-left: 0pt">Total face value of notes</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">478,957</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less: Discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,454</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">101,346</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">377,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">   September 30,</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom">December 31,</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"> </td><td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">2019</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"> </td><td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">2018</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 56%; text-align: left; padding-left: 0pt">Annual dividend yield</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.78 - 1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.77 - 1.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="text-align: left; padding-left: 0pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.44% - 2.52%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 2.07% - 2.57%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 274% - 294%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 257% - 293%</td><td style="text-align: left"> </td></tr></table>

-98944

28745

EX-101.SCH 7 igmb-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 1 - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 3 - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 5 - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 6 - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 7 - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 8 - Convertible Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 9 - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 10 - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 11 - Stock Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 12 - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 13 - Concentrations and Credit Risk link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Note 14 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 15 - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 16 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 4 - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 5 - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 7 - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 8 - Convertible Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Note 9 - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Note 3 - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Note 4 - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Note 4 - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Note 5 - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Note 5 - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Note 7 - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Note 7 - Stock Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Note 7 - Stock Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Note 7 - Stock Based Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Note 8 - Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Note 8 - Convertible Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Note 9 - Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Note 10 - Note Payable (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Note 11 - Stock Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Note 13 - Concentrations and Credit Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Note 14 - Related Party Transactions (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Note 15 - Commitments and Contingencies (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Note 16- Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 igmb-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 igmb-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 igmb-20190930_lab.xml XBRL LABEL FILE Property, Plant and Equipment, Type [Axis] Office equipment and fixtures Range [Axis] Minimum Maximum Computer hardware Computer software Development equipment Finite-Lived Intangible Assets by Major Class [Axis] Software Technology license Customer contracts In process research and development FDA 510K clearance Antidilutive Securities [Axis] Options Warrant Award Type [Axis] Options One Options Two Warrants One Warrants Two Warrants Three Warrants Four Warrants Five Short-term Debt, Type [Axis] Noteholder Debt Security Category [Axis] Principal Accrued interest Concentration Risk Benchmark [Axis] Sales [Member] Customer [Axis] First Customers [Member] Second Customers [Member] Accounts Receivable [Member] One Customer [Member] 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note 8% Convertible Note Type of Arrangement and Non-arrangement Transactions [Axis] Clinigence Holdings Long-term Debt, Type [Axis] Secured Promissory Notes [Member] Convertible Debt Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Treasury Stock Document and Entity Information: Entity Registrant Name Document Type Document Period End Date Amendment Flag Entity Central Index Key Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Filer Category Entity's Reporting Status Current Entity Emerging Growth Company Entity Small Business Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Ex Transition Period Entity Shell Company File Number Document Fiscal Year Focus Document Fiscal Period Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable Inventory Prepaid expenses Total current assets Other assets Property and equipment, net Intangilbe assets, net Deposits Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses Accrued interest on notes payable Amounts due to related parties Deferred revenue Notes payable Convertible notes payable, net Derivative liability Total current liabilities Stockholders' equity Preferred stock, $.001 par value; authorized - 100,000,000 shares;issued and outstanding - 0 shares in 2019 and 2018, respectively Common stock, $.001 par value; authorized - 800,000,000 shares; 797,108 and 429,720 shares issued and 777,108 and 409,720 shares outstanding (net of treasury shares) as of September 30, 2019 and December 31, 2018, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity before Treasury stock Less: Treasury stock; 10,000,000 shares, at cost Total stockholders' equity Liabilities and equity Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock Income Statement [Abstract] Sales Cost of Sales Gross profit (loss) Operating Expenses General and administrative expenses Amortization Total operating expenses Loss from operations Other income (expenses) Change in fair value of derivative liability Loss on extinguishment of debt Interest Expense Total other income (expenses) Net loss Basic and fully diluted loss per common share: Net loss per common share Weighted average common shares outstanding - basic and fully diluted Statement [Table] Statement [Line Items] Stockholders' Equity, beginning of period, Value Stockholders' Equity, beginning of period, Shares Common stock issued for cash, Value Common stock issued for cash, Shares Compensation for vested stock options Notes payable and accrued interest converted to common stock, Value Notes payable and accrued interest converted to common stock, Shares Amounts due to related parties converted to common stock, value Amounts due to related parties converted to common stock, shares Common stock issued for services, Value Common stock issued for services, Shares Net loss Stockholders' Equity, end of period, Value Stockholders' Equity, end of period, Shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities Depreciation Non cash interest expense Stock-based compensation expense Loss on extinguishment of debt Change in fair value of derivative liability Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Deposits Accounts payable and accrued expenses Deferred revenue NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible debentures Repayments of convertible debentures Proceeds from sale of common stock Proceeds from notes payable Proceeds from related party loans Repayments of related party loans NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE (DECREASE) IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid during the period for Interest Non-cash investing and financing activities: Debt discount related to derivative liability Notes payable converted to common stock Common stock issued in payment of accrued interest Disclosure Text Block [Abstract] Note 1 - Organization and Basis of Presentation Note 2 - Summary of Significant Accounting Policies Note 3 - Going Concern Note 4 - Property and Equipment Note 5 - Intangible Assets Note 6 - Earnings (Loss) Per Common Share Note 7 - Stock Based Compensation EX-101.PRE 11 igmb-20190930_pre.xml XBRL PRESENTATION FILE XML 12 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Earnings (Loss) Per Common Share

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 6 - Earnings (Loss) Per Common Share

Note 6 - Earnings (Loss) Per Common Share

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Stock options		2,000,000		8,463,000		2,000,000		8,463,000
Stock warrants		1,625,000		1,900,000		1,625,000		1,900,000
Convertible debt		600		410,802		600		410,802
Total shares excluded from calculation		3,625,600		10,773,802		3,625,600		10,773,802

XML 13 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Note Payable

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 10 - Note Payable

Note 10 – Notes Payable

XML 14 R35.htm IDEA: XBRL DOCUMENT

Note 3 - Going Concern (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Accumulated deficit	$ (13,966,325)	$ (12,462,814)
Working capital deficit	$ (1,411,857)

XML 15 R31.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Liabilities:
Balance of derivative liabilities - beginning of year	$ 288,242	$ 66,059
Issued	292,913	1,122,211
Converted	(482,211)	(928,773)
Change in fair value of derivative liabilities	(98,944)	28,745
Balance of derivative liabilities - end of period	$ 0	$ 288,242

XML 16 R39.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disclosure Text Block [Abstract]
Amortization expense	$ 521,902	$ 521,902

XML 17 R50.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations and Credit Risk (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
FDIC	$ 250,000
Sales [Member] \| First Customers [Member]
Concentration percentage	15.00%	66.00%
Sales [Member] \| Second Customers [Member]
Concentration percentage	14.00%	32.00%
Accounts Receivable [Member] \| Second Customers [Member]
Concentration percentage		19.00%
Accounts Receivable [Member] \| One Customer [Member]
Concentration percentage	100.00%	77.00%

XML 18 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 170 276 1 false 46 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://igambit.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://igambit.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://igambit.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://igambit.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://igambit.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://igambit.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - Note 1 - Organization and Basis of Presentation Sheet http://igambit.com/role/Note1-OrganizationAndBasisOfPresentation Note 1 - Organization and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPolicies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note 3 - Going Concern Sheet http://igambit.com/role/Note3-GoingConcern Note 3 - Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 - Property and Equipment Sheet http://igambit.com/role/Note4-PropertyAndEquipment Note 4 - Property and Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Note 5 - Intangible Assets Sheet http://igambit.com/role/Note5-IntangibleAssets Note 5 - Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Note 6 - Earnings (Loss) Per Common Share Sheet http://igambit.com/role/Note6-EarningsLossPerCommonShare Note 6 - Earnings (Loss) Per Common Share Notes 12 false false R13.htm 00000013 - Disclosure - Note 7 - Stock Based Compensation Sheet http://igambit.com/role/Note7-StockBasedCompensation Note 7 - Stock Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Note 8 - Convertible Debt Sheet http://igambit.com/role/Note8-ConvertibleDebt Note 8 - Convertible Debt Notes 14 false false R15.htm 00000015 - Disclosure - Note 9 - Derivative Liability Sheet http://igambit.com/role/Note9-DerivativeLiability Note 9 - Derivative Liability Notes 15 false false R16.htm 00000016 - Disclosure - Note 10 - Note Payable Sheet http://igambit.com/role/Note10-NotePayable Note 10 - Note Payable Notes 16 false false R17.htm 00000017 - Disclosure - Note 11 - Stock Transactions Sheet http://igambit.com/role/Note11-StockTransactions Note 11 - Stock Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Note 12 - Income Taxes Sheet http://igambit.com/role/Note12-IncomeTaxes Note 12 - Income Taxes Notes 18 false false R19.htm 00000019 - Disclosure - Note 13 - Concentrations and Credit Risk Sheet http://igambit.com/role/Note13-ConcentrationsAndCreditRisk Note 13 - Concentrations and Credit Risk Notes 19 false false R20.htm 00000020 - Disclosure - Note 14 - Related Party Transactions Sheet http://igambit.com/role/Note14-RelatedPartyTransactions Note 14 - Related Party Transactions Notes 20 false false R21.htm 00000021 - Disclosure - Note 15 - Commitments and Contingencies Sheet http://igambit.com/role/Note15-CommitmentsAndContingencies Note 15 - Commitments and Contingencies Notes 21 false false R22.htm 00000022 - Disclosure - Note 16 - Subsequent Events Sheet http://igambit.com/role/Note16-SubsequentEvents Note 16 - Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies Note 2 - Summary of Significant Accounting Policies (Policies) Policies http://igambit.com/role/Note2-SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://igambit.com/role/Note2-SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Note 4 - Property and Equipment (Tables) Sheet http://igambit.com/role/Note4-PropertyAndEquipmentTables Note 4 - Property and Equipment (Tables) Tables http://igambit.com/role/Note4-PropertyAndEquipment 25 false false R26.htm 00000026 - Disclosure - Note 5 - Intangible Assets (Tables) Sheet http://igambit.com/role/Note5-IntangibleAssetsTables Note 5 - Intangible Assets (Tables) Tables http://igambit.com/role/Note5-IntangibleAssets 26 false false R27.htm 00000027 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Tables) Sheet http://igambit.com/role/Note6-EarningsLossPerCommonShareTables Note 6 - Earnings (Loss) Per Common Share (Tables) Tables http://igambit.com/role/Note6-EarningsLossPerCommonShare 27 false false R28.htm 00000028 - Disclosure - Note 7 - Stock Based Compensation (Tables) Sheet http://igambit.com/role/Note7-StockBasedCompensationTables Note 7 - Stock Based Compensation (Tables) Tables http://igambit.com/role/Note7-StockBasedCompensation 28 false false R29.htm 00000029 - Disclosure - Note 8 - Convertible Debt (Tables) Sheet http://igambit.com/role/Note8-ConvertibleDebtTables Note 8 - Convertible Debt (Tables) Tables http://igambit.com/role/Note8-ConvertibleDebt 29 false false R30.htm 00000030 - Disclosure - Note 9 - Derivative Liability (Tables) Sheet http://igambit.com/role/Note9-DerivativeLiabilityTables Note 9 - Derivative Liability (Tables) Tables http://igambit.com/role/Note9-DerivativeLiability 30 false false R31.htm 00000031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetails Note 2 - Summary of Significant Accounting Policies (Details) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 1) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetails1 Note 2 - Summary of Significant Accounting Policies (Details 1) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details 2) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetails2 Note 2 - Summary of Significant Accounting Policies (Details 2) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narratives) Sheet http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesDetailsNarratives Note 2 - Summary of Significant Accounting Policies (Details Narratives) Details http://igambit.com/role/Note2-SummaryOfSignificantAccountingPoliciesTables 34 false false R35.htm 00000035 - Disclosure - Note 3 - Going Concern (Details Narrative) Sheet http://igambit.com/role/Note3-GoingConcernDetailsNarrative Note 3 - Going Concern (Details Narrative) Details http://igambit.com/role/Note3-GoingConcern 35 false false R36.htm 00000036 - Disclosure - Note 4 - Property and Equipment (Details) Sheet http://igambit.com/role/Note4-PropertyAndEquipmentDetails Note 4 - Property and Equipment (Details) Details http://igambit.com/role/Note4-PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - Note 4 - Property and Equipment (Details Narrative) Sheet http://igambit.com/role/Note4-PropertyAndEquipmentDetailsNarrative Note 4 - Property and Equipment (Details Narrative) Details http://igambit.com/role/Note4-PropertyAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - Note 5 - Intangible Assets (Details) Sheet http://igambit.com/role/Note5-IntangibleAssetsDetails Note 5 - Intangible Assets (Details) Details http://igambit.com/role/Note5-IntangibleAssetsTables 38 false false R39.htm 00000039 - Disclosure - Note 5 - Intangible Assets (Details Narrative) Sheet http://igambit.com/role/Note5-IntangibleAssetsDetailsNarrative Note 5 - Intangible Assets (Details Narrative) Details http://igambit.com/role/Note5-IntangibleAssetsTables 39 false false R40.htm 00000040 - Disclosure - Note 6 - Earnings (Loss) Per Common Share (Details) Sheet http://igambit.com/role/Note6-EarningsLossPerCommonShareDetails Note 6 - Earnings (Loss) Per Common Share (Details) Details http://igambit.com/role/Note6-EarningsLossPerCommonShareTables 40 false false R41.htm 00000041 - Disclosure - Note 7 - Stock Based Compensation (Details) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails Note 7 - Stock Based Compensation (Details) Details http://igambit.com/role/Note7-StockBasedCompensationTables 41 false false R42.htm 00000042 - Disclosure - Note 7 - Stock Based Compensation (Details 1) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails1 Note 7 - Stock Based Compensation (Details 1) Details http://igambit.com/role/Note7-StockBasedCompensationTables 42 false false R43.htm 00000043 - Disclosure - Note 7 - Stock Based Compensation (Details 2) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails2 Note 7 - Stock Based Compensation (Details 2) Details http://igambit.com/role/Note7-StockBasedCompensationTables 43 false false R44.htm 00000044 - Disclosure - Note 7 - Stock Based Compensation (Details 3) Sheet http://igambit.com/role/Note7-StockBasedCompensationDetails3 Note 7 - Stock Based Compensation (Details 3) Details http://igambit.com/role/Note7-StockBasedCompensationTables 44 false false R45.htm 00000045 - Disclosure - Note 8 - Convertible Debt (Details) Sheet http://igambit.com/role/Note8-ConvertibleDebtDetails Note 8 - Convertible Debt (Details) Details http://igambit.com/role/Note8-ConvertibleDebtTables 45 false false R46.htm 00000046 - Disclosure - Note 8 - Convertible Debt (Details Narrative) Sheet http://igambit.com/role/Note8-ConvertibleDebtDetailsNarrative Note 8 - Convertible Debt (Details Narrative) Details http://igambit.com/role/Note8-ConvertibleDebtTables 46 false false R47.htm 00000047 - Disclosure - Note 9 - Derivative Liability (Details) Sheet http://igambit.com/role/Note9-DerivativeLiabilityDetails Note 9 - Derivative Liability (Details) Details http://igambit.com/role/Note9-DerivativeLiabilityTables 47 false false R48.htm 00000048 - Disclosure - Note 10 - Note Payable (Details Narratives) Sheet http://igambit.com/role/Note10-NotePayableDetailsNarratives Note 10 - Note Payable (Details Narratives) Details http://igambit.com/role/Note10-NotePayable 48 false false R49.htm 00000049 - Disclosure - Note 11 - Stock Transactions (Details Narrative) Sheet http://igambit.com/role/Note11-StockTransactionsDetailsNarrative Note 11 - Stock Transactions (Details Narrative) Details http://igambit.com/role/Note11-StockTransactions 49 false false R50.htm 00000050 - Disclosure - Note 13 - Concentrations and Credit Risk (Details Narrative) Sheet http://igambit.com/role/Note13-ConcentrationsAndCreditRiskDetailsNarrative Note 13 - Concentrations and Credit Risk (Details Narrative) Details http://igambit.com/role/Note13-ConcentrationsAndCreditRisk 50 false false R51.htm 00000051 - Disclosure - Note 14 - Related Party Transactions (Details Narratives) Sheet http://igambit.com/role/Note14-RelatedPartyTransactionsDetailsNarratives Note 14 - Related Party Transactions (Details Narratives) Details http://igambit.com/role/Note14-RelatedPartyTransactions 51 false false R52.htm 00000052 - Disclosure - Note 15 - Commitments and Contingencies (Details Narratives) Sheet http://igambit.com/role/Note15-CommitmentsAndContingenciesDetailsNarratives Note 15 - Commitments and Contingencies (Details Narratives) Details http://igambit.com/role/Note15-CommitmentsAndContingencies 52 false false R53.htm 00000053 - Disclosure - Note 16- Subsequent Events (Details Narrative) Sheet http://igambit.com/role/Note16-SubsequentEventsDetailsNarrative Note 16- Subsequent Events (Details Narrative) Details 53 false false All Reports Book All Reports igmb-20190930.xml igmb-20190930.xsd igmb-20190930_cal.xml igmb-20190930_def.xml igmb-20190930_lab.xml igmb-20190930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true XML 19 R45.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Total face value of notes	$ 75,000	$ 478,957
Less: Discount	2,454	101,346
Balance	$ 72,546	$ 377,611

XML 20 R41.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disclosure Text Block [Abstract]
Options, Outstanding, Beginning Balance	20,500,000	8,463,000
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.03	$ 0.07
Options, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.07
Options, Outstanding, Beginning Weighted Average Remaining Contractual Term	7 years 6 months 7 days	7 years 4 months 28 days
Options, Canceled	(18,250,000)
Options, Canceled, Weighted Average Exercise Price	$ 0.03
Options, Expired	(250,000)
Options, Expired , Weighted Average Exercise Price	$ 0.05
Options, Outstanding, Ending Balance	2,000,000	8,463,000
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.07	$ 0.07
Options, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.07	$ 0.07
Options, Outstanding, Ending Weighted Average Remaining Contractual Term	6 years 5 months 27 days	6 years 7 months 28 days

XML 21 R49.htm IDEA: XBRL DOCUMENT

Note 11 - Stock Transactions (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Oct. 25, 2019	Sep. 30, 2019	Dec. 31, 2018
Common stock, shares authorized		800,000,000	800,000,000
Reverse stock split	1-for-500
Noteholder
Debt Conversion, Converted Instrument, Shares Issued		365,388
Noteholder \| Principal
Debt Conversion, Converted Instrument, Amount		$ 326,189
Noteholder \| Accrued interest
Debt Conversion, Converted Instrument, Amount		$ 19,868

XML 22 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,503,511)	$ (1,944,799)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	742	1,295
Amortization	521,902	521,902
Non cash interest expense	231,563	312,412
Stock-based compensation expense	1,025	88,800
Loss on extinguishment of debt	262,566	233,734
Change in fair value of derivative liability	(98,944)	128,100
Changes in operating assets and liabilities:
Accounts receivable	4,871	(19,727)
Inventory	85	0
Prepaid expenses and other current assets	(5,971)	39,377
Deposits	1,720	0
Accounts payable and accrued expenses	260,195	(68,928)
Deferred revenue	(8,592)	(4,933)
NET CASH USED IN OPERATING ACTIVITIES	(332,349)	(712,767)
CASH FLOWS FROM INVESTING ACTIVITIES	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures	168,500	676,500
Repayments of convertible debentures	(257,693)	0
Proceeds from sale of common stock	0	30,000
Proceeds from notes payable	443,093	0
Proceeds from related party loans	11,254	0
Repayments of related party loans	(23,145)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	342,009	706,500
NET INCREASE (DECREASE) IN CASH	9,660	(6,267)
CASH - BEGINNING OF PERIOD	369	9,449
CASH - END OF PERIOD	10,029	3,182
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for Interest	2,752	2,563
Non-cash investing and financing activities:
Debt discount related to derivative liability	222,500	533,249
Notes payable converted to common stock	326,189	387,000
Common stock issued in payment of accrued interest	$ 19,868	$ 23,746

XML 23 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 10,029	$ 369
Accounts receivable	10,000	14,871
Inventory	26,988	27,073
Prepaid expenses	5,971	0
Total current assets	52,988	42,313
Other assets
Property and equipment, net	1,376	2,118
Intangilbe assets, net	2,050,113	2,572,015
Deposits	300	2,020
Total Assets	2,104,777	2,618,466
Current liabilities
Accounts payable and accrued expenses	740,465	480,270
Accrued interest on notes payable	27,165	32,265
Amounts due to related parties	128,476	145,367
Deferred revenue	600	9,192
Notes payable	495,593	52,500
Convertible notes payable, net	72,546	377,611
Derivative liability	0	288,242
Total current liabilities	1,464,845	1,385,447
Stockholders' equity
Preferred stock, $.001 par value; authorized - 100,000,000 shares;issued and outstanding - 0 shares in 2019 and 2018, respectively	0	0
Common stock, $.001 par value; authorized - 800,000,000 shares; 797,108 and 429,720 shares issued and 777,108 and 409,720 shares outstanding (net of treasury shares) as of September 30, 2019 and December 31, 2018, respectively	797	430
Additional paid-in capital	15,605,460	14,695,403
Accumulated deficit	(13,966,325)	(12,462,814)
Total stockholders' equity before Treasury stock	1,639,932	2,233,019
Less: Treasury stock; 10,000,000 shares, at cost	(1,000,000)	(1,000,000)
Total stockholders' equity	639,932	1,233,019
Liabilities and equity	$ 2,104,777	$ 2,618,466

XML 24 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Schedule of stock option activities

Stock option activity during the nine months ended September 30, 2019 and 2018 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Life (Years)
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at September 30, 2018		8,463,000		$	0.07		0.07		6.66
Options outstanding at December 31, 2018		20,500,000			0.03		0.03		7.52
Options cancelled (1)		(18,250,000	)		0.03		—
Options expired		(250,000	)		0.05		—
Options outstanding at September 30, 2019		2,000,000		$	0.07	$	0.07		6.49

Schedule of stock options outstanding

Options outstanding at September 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	March 24, 2015		200,000		200,000	$	0.01		March 24, 2020
	June 6, 2017		1,800,000		1,800,000	$	0.07		June 6, 2027
	Total		2,000,000		2,000,000

Schedule of Warrants, Activity

Warrant activity during the nine months ended September 30, 2019 and 2018 follows:

	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2017		400,000		$	0.62	$	0.10		3.27
Warrant granted		1,500,000			0.05		—
Warrants outstanding at September 30, 2018		1,900,000		$	0.21	$	0.12		3.49
Warrants outstanding at December 31, 2018		1,875,000		$	0.12	$	0.12		3.24
Warrants expired		(250,000	)		0.73		—
Warrants outstanding at September 30, 2019		1,625,000		$	0.03	$	0.03		2.90

Schedule of Outstanding Warrants

Warrants outstanding at September 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	January 1, 2017		50,000		50,000	$	0.25		October 10, 2021
	January 1, 2017		50,000		50,000	$	0.50		November 7, 2021
	January 5, 2017		25,000		25,000	$	0.50		January 5, 2022
	February 5, 2018		750,000		750,000	$	0.05		February 5, 2023
	April 27, 2018		750,000		750,000	$	0.05		April 27, 2023
	Total		1,625,000		1,625,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 25 R20.htm IDEA: XBRL DOCUMENT

Note 14 - Related Party Transactions

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 14 - Related Party Transactions

Note 14 - Related Party Transactions

Amounts Due to Related Parties

XML 26 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Fair value assets and liabilities measured on recurring basis

The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the nine months ended September 30, 2019 and year ended December 31, 2018.

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Schedule of estimated lives of respective assets

Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Schedule of estimated lives of the respective assets of intangible assets

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

XML 27 R48.htm IDEA: XBRL DOCUMENT

Note 10 - Note Payable (Details Narratives) - USD ($)			1 Months Ended	9 Months Ended
Note 10 - Note Payable (Details Narratives) - USD ($)	Sep. 09, 2019	Aug. 06, 2019	Jun. 24, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Notes payable from discontinued operations				$ 52,500		$ 52,500
Proceeds from notes payable				$ 443,093	$ 0
Secured Promissory Notes [Member]
Proceeds from notes payable	$ 25,000	$ 25,000	$ 393,093
Interest rate			6.00%

XML 28 R44.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details 3)	9 Months Ended
Note 7 - Stock Based Compensation (Details 3)	Sep. 30, 2019 $ / shares shares
Number of Outstanding	1,625,000
Number Exercisable	1,625,000
Warrants One
Issued Date	Jan. 01, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.25
Expiration Date	Oct. 10, 2021
Warrants Two
Issued Date	Jan. 01, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	Nov. 07, 2021
Warrants Three
Issued Date	Jan. 05, 2017
Number of Outstanding	25,000
Number Exercisable	25,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	Jan. 05, 2022
Warrants Four
Issued Date	Feb. 05, 2018
Number of Outstanding	750,000
Number Exercisable	750,000
Exercise price \| $ / shares	$ 0.05
Expiration Date	Feb. 05, 2023
Warrants Five
Issued Date	Apr. 27, 2018
Number of Outstanding	750,000
Number Exercisable	750,000
Exercise price \| $ / shares	$ 0.05
Expiration Date	Apr. 27, 2023

XML 29 R40.htm IDEA: XBRL DOCUMENT

Note 6 - Earnings (Loss) Per Common Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total shares excluded from calculation	3,625,600	10,773,802	3,625,600	10,773,802
Options
Total shares excluded from calculation	2,000,000	8,463,000	2,000,000	8,463,000
Warrant
Total shares excluded from calculation	1,625,000	1,900,000	1,625,000	1,900,000
Convertible Debt
Total shares excluded from calculation	600	410,802	600	410,802

XML 30 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Basis of Presentation

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 1 - Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Interim Financial Statements

XML 31 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ .001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	797,108	429,720
Common stock, shares outstanding	777,108	409,720
Treasury stock	10,000,000	10,000,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 15 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 15 - Commitments and Contingencies

Note 15 – Commitments and Contingencies

Lease Commitment

Rent expense of $17,711 and $21,363 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Employment Arrangements With Executive Officers

XML 33 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Schedule of property, plant and equipment

Property and equipment are carried at cost and consist of the following at September 30, 2019 and December 31, 2018:

	2019		2018
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		9,588		8,846
	$	1,376	$	2,118

XML 34 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Schedule of convertible notes payable

Convertible notes payable at September 30, 2019 and December 31, 2018 are summarized as follows:

	2019		2018
Total face value of notes	$	75,000	$	478,957
Less: Discount		2,454		101,346
Balance	$	72,546	$	377,611

XML 35 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 7 - Stock Based Compensation

Note 7 – Stock Based Compensation

Options

Stock option activity during the nine months ended September 30, 2019 and 2018 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Life (Years)
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at September 30, 2018		8,463,000		$	0.07		0.07		6.66
Options outstanding at December 31, 2018		20,500,000			0.03		0.03		7.52
Options cancelled (1)		(18,250,000	)		0.03		—
Options expired		(250,000	)		0.05		—
Options outstanding at September 30, 2019		2,000,000		$	0.07	$	0.07		6.49

(1) Options to iGambit management and key consultants were cancelled in connection with the reverse stock split prior to the reverse merger agreement consummated on October 29, 2019.

Options outstanding at September 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	March 24, 2015		200,000		200,000	$	0.01		March 24, 2020
	June 6, 2017		1,800,000		1,800,000	$	0.07		June 6, 2027
	Total		2,000,000		2,000,000

Warrants

Warrant activity during the nine months ended September 30, 2019 and 2018 follows:

	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2017		400,000		$	0.62	$	0.10		3.27
Warrant granted		1,500,000			0.05		—
Warrants outstanding at September 30, 2018		1,900,000		$	0.21	$	0.12		3.49
Warrants outstanding at December 31, 2018		1,875,000		$	0.12	$	0.12		3.24
Warrants expired		(250,000	)		0.73		—
Warrants outstanding at September 30, 2019		1,625,000		$	0.03	$	0.03		2.90

Warrants outstanding at September 30, 2019 consist of:

Date		Number		Number		Exercise		Expiration
Issued		Outstanding		Exercisable		Price		Date
	January 1, 2017		50,000		50,000	$	0.25		October 10, 2021
	January 1, 2017		50,000		50,000	$	0.50		November 7, 2021
	January 5, 2017		25,000		25,000	$	0.50		January 5, 2022
	February 5, 2018		750,000		750,000	$	0.05		February 5, 2023
	April 27, 2018		750,000		750,000	$	0.05		April 27, 2023
	Total		1,625,000		1,625,000

XML 36 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Stock Transactions

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 11 - Stock Transactions

Note 11 – Stock Transactions

Designation of Preferred Stock

Reverse Stock Split

Common Stock Issued

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 37 R38.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Details) - USD ($)	9 Months Ended
Note 5 - Intangible Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Intangible Assets, Gross	$ 3,801,771	$ 3,801,771
Less: Accumulated amortization	1,751,658	1,229,756
Intangible Assets, Net	2,050,113	2,572,015
Software
Intangible Assets, Gross	$ 156,925	156,925
Intangible assets useful life	5 years
Customer contracts
Intangible Assets, Gross	$ 644,846	644,846
Intangible assets useful life	10 years
FDA 510K clearance
Intangible Assets, Gross	$ 1,396,000	1,396,000
Intangible assets useful life	5 years
Technology license
Intangible Assets, Gross	$ 1,000,000	1,000,000
Intangible assets useful life	5 years
In process research and development
Intangible Assets, Gross	$ 604,000	$ 604,000
Intangible assets useful life	Indefinite

XML 38 R34.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Narratives) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Disclosure Text Block [Abstract]
Advertising costs	$ 329	$ 0
Deferred revenue	$ 600		$ 9,192

XML 39 R30.htm IDEA: XBRL DOCUMENT

Note 9 - Derivative Liability (Tables)

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Schedule of Valuation Assumptions

	September 30,	December 31,
	2019	2018
Annual dividend yield	—	—
Expected life (years)	0.78 - 1.0	0.77 - 1.0
Risk-free interest rate	2.44% - 2.52%	2.07% - 2.57%
Expected volatility	274% - 294%	257% - 293%

XML 40 R51.htm IDEA: XBRL DOCUMENT

Note 14 - Related Party Transactions (Details Narratives) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Amounts due to related parties	$ 128,476	$ 145,367

XML 41 R46.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt (Details Narrative) - USD ($)						1 Months Ended						9 Months Ended
Note 8 - Convertible Debt (Details Narrative) - USD ($)	Jan. 03, 2019	Aug. 13, 2018	May 03, 2018	Mar. 06, 2018	Jan. 10, 2018	Jun. 24, 2019	Mar. 29, 2019	Feb. 15, 2019	Sep. 17, 2018	Jun. 25, 2018	Mar. 30, 2017	Sep. 30, 2019	Sep. 30, 2018
Interest expense on the convertible notes												$ 218,454	$ 119,603
Interest expense on the convertible debentures												$ 5,589	$ 5,589
8% Convertible Note
Debt Conversion, Converted Instrument, Shares Issued												97,388
Principal payment						$ 94,268
Payment of accrued interest						7,417
Prepayment penalty						5,000
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount					$ 240,000							$ 71,732
Interest rate					8.00%
Maturity date					Jul. 10, 2018
8% Convertible Note \| Accrued interest
Debt Conversion, Converted Instrument, Amount												$ 5,366
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount											$ 75,000
Interest rate											8.00%
Maturity date											Jun. 25, 2018
8% Convertible Note
Debt Conversion, Converted Instrument, Shares Issued												70,893
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount				$ 126,000								$ 60,000
Interest rate				8.00%
Maturity date				Mar. 06, 2019
8% Convertible Note \| Accrued interest
Debt Conversion, Converted Instrument, Amount												$ 4,342
8% Convertible Note
Debt Conversion, Converted Instrument, Shares Issued												51,349
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount			$ 83,500									$ 53,957
Interest rate			8.00%
Maturity date			May 03, 2019
8% Convertible Note \| Accrued interest
Debt Conversion, Converted Instrument, Amount												$ 4,600
8% Convertible Note
Debt Conversion, Converted Instrument, Shares Issued												29,719
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount										$ 53,000		$ 38,000
Interest rate										8.00%
Maturity date										Apr. 15, 2019
8% Convertible Note \| Accrued interest
Debt Conversion, Converted Instrument, Amount												$ 2,120
8% Convertible Note
Debt Conversion, Converted Instrument, Shares Issued												52,495
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount		$ 53,000										$ 53,000
Interest rate		8.00%
Maturity date		May 30, 2019
8% Convertible Note \| Accrued interest
Debt Conversion, Converted Instrument, Amount												$ 2,120
8% Convertible Note
Debt Conversion, Converted Instrument, Shares Issued												63,525
8% Convertible Note \| Principal
Debt Conversion, Converted Instrument, Amount									$ 33,000			$ 33,000
Interest rate									8.00%
Maturity date									Jun. 30, 2019
8% Convertible Note \| Accrued interest
Debt Conversion, Converted Instrument, Amount												$ 1,320
8% Convertible Note
Debt Conversion, Converted Instrument, Amount	$ 38,000
Interest rate	8.00%
Maturity date	Oct. 30, 2019
Principal payment						38,000
Payment of accrued interest						1,659
Prepayment penalty						7,600
8% Convertible Note
Debt Conversion, Converted Instrument, Amount								$ 38,000
Interest rate								8.00%
Maturity date								Nov. 30, 2019
Principal payment						38,000
Payment of accrued interest						1,259
Prepayment penalty						7,600
8% Convertible Note
Debt Conversion, Converted Instrument, Amount							$ 38,000
Interest rate							8.00%
Maturity date							Feb. 15, 2020
Principal payment						38,000
Payment of accrued interest						810
Prepayment penalty						7,600
8% Convertible Note
Debt Conversion, Converted Instrument, Amount							$ 38,000
Interest rate							8.00%
Maturity date							Mar. 15, 2020
Principal payment						38,000
Payment of accrued interest						810
Prepayment penalty						$ 7,600

XML 42 R42.htm IDEA: XBRL DOCUMENT

Note 7 - Stock Based Compensation (Details 1) - $ / shares	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Number of Outstanding	2,000,000	20,500,000	8,463,000	8,463,000
Number Exercisable	2,000,000
Exercise price	$ 0.07	$ 0.03	$ 0.07	$ 0.07
Options One
Issued Date	Mar. 24, 2015
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 0.01
Options outstanding Expiration Date	Mar. 24, 2020
Options Two
Issued Date	Jun. 06, 2017
Number of Outstanding	1,800,000
Number Exercisable	1,800,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 06, 2027

XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Policy Text Block [Abstract]

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

Use of Estimates in the Preparation of Financial Statements

Fair Value Measurements

Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

	2019			2018
Liabilities:
Balance of derivative liabilities - beginning of period	$	288,242		$	66,059
Issued		292,913			1,122,211
Converted		(482,211	)		(928,773	)
Change in fair value recognized in operations		(98,944	)		28,745
Balance of derivative liabilities - end of period	$	—		$	288,242

Convertible Instruments

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Revenue Recognition

Revenue Recognition

Clinigence Holdings, Inc. is a holding company and has no sources of revenue.

Advertising Costs

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs of $329 and $0 were charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

Cash and Cash Equivalents

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

Accounts Receivable

Inventory

Inventory

Inventory consisting of finished products is stated at the lower of cost or net realizable value.

Property and equipment and depreciation

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Amortization

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

Long-Lived Assets

Long-Lived Assets

Deferred Revenue

Deferred Revenue

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 45 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Earnings (Loss) Per Common Share (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Computation of diluted net income (loss) per share

The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the nine months ended September 30, 2019 and 2018 as the result would be anti-dilutive.

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Stock options		2,000,000		8,463,000		2,000,000		8,463,000
Stock warrants		1,625,000		1,900,000		1,625,000		1,900,000
Convertible debt		600		410,802		600		410,802
Total shares excluded from calculation		3,625,600		10,773,802		3,625,600		10,773,802

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

@F(*FE9%-G-S.$!TCM%W?5FXE6D=(R " MQ1 L022IB]2A%T<].)$WY7VZ$>,!;1KU7<*SMZA);'9!^G<)^P7BND=3)NCJ MT0\K7$F[,05?IXY_7?1^F2F 1E6L\@7!\\[8!2MMNT%3"SV"VC$L9+W/@ /73V>P?,HB>UG5;[(TQ)8Z4]9NMHM+V$'G_A]T8E,Y?RBI^O@'J-- MNLZB!UC&G.@^'7SK\A4 YLU\5Z!5.Q&?.T\C2P54B-)HR0\1N\$O'Y;Y? FZ M0_:![ 6 &L#ZV;9*@+=\AI_(F?WLLOER4ZR*^\=HG98?@&UT5'.'\,9L M,P(B]&;B1L6I*[39KW$_^BXBZ>/?UNDF)1=M[H0HR!P+\4Z>(?IN*KQ"ZVR! MIF1UEV B_8T1PQR5^)L M7P-RMTQW"G;P,5^@A+DJ]@OA[%NX]/AH16, (G2=G9D+!^U)(JF6^=T./Y!P MJP4$'%IF^7JV+RO!<<0Z&":O5=MBBS817"%/SW!D8^;);99%?+-'@&!$[?*U MLC;U6WMW\(;= 2(7#^1C24^1^BQ0;D!!Q;EYLW1%_)8B4<3G$G"N,)8MX?=9 MEFV8^.&]118G)J/@)8[I7IW,3NGH]MJ\U+::G/<4I@?H)')NPS(%O*'5;%$R M*AE'@3(6Y8*V])#OE@J?R#> J?NY.9V7<)81AH@0^-_MX3 G9]T^ON!==J\/ MX/;L?W6BQ(4E E.EYP M@;/'Z,?S\[>,X+"/50:G&=HL'B]-6FP!O6%"?:4R=BKC:U-'-CY!,.;,VV#H M!A>R0G$9)$/X3A'#2%<5X0&0M Q7L\GPM@)QH_6D;-#=NH3:PECVN^A$UL@- M(_#D^C6L%.@ WF8WW&1KOK?=.6>]=25Y:\_(/_4U2=F0Q0#!&(%[DNSL-NK"\VZ<,[S+9P+D!D! M9U"\2(#?W^[7:\0?])GD]YO\#HX1*)6$&.#9O 4@S0/J%XD,"3'C7N_[9TP$ MD@2 *(>K4RF4!LPY'"]8Z+M+YZFC(6K4Y0EQ "@#W$ B5\(_E)F):#K&#:5" MD#)SV/?32^R[1&WK?^N):=(J(B64+O M-"'&/7N@X-9AQ-:6Q"L+Y:T!;B1$JW)9$!#/=?H!KJ->-)%W4#OWZZV05[RT MZ=T=W%;:34EXBB]9&SB'%5[Z>V$E3];F<%56M:T_HU)^"QZV/L'C;F;;VB0 M1?SE6M5NZ!O(&79P#Y4F5G.B'HL<=EXR6V2!U4"J$[T$\JK8F/.:/!O.81JT M6Q1T)")-?=WUY$[X$;S*-) K04)XL"DU%PA $BB$(XNU[$HN:SFX,Z MDJ(GST")626S;KDG)#JB]H13TP=$#)B#!Z7-D"SG2]%]5"C&B%@!"$5ECD>P MBY; OXH2Q4 *>R!_5Z5%CW0+X/@D-P6@ ]NP>T&I9)[N*X,#0,S+W1E<3M#5 M4S0!*/ZARMP=LG2-*W@D+=!B0;$O90[&N&)SS[/-@6^".E',5OF]B'O.RESP MZA7AU"/*M^0#Y=4X$^F=:NJ$R(_:UCY=63M4R?N'.P@S%/<9F7_H M7K,EZ"ZC[0([VR/0R%*JK4/:MD)T\P%VG0K"? M\";G08L&,#;148@YB@8[Y MH!!#2Y)\T1!'ZZ#[ N_;L S@@);4 Z!U*^!T K,RKSYT$(T5(##%UH >X4(L MK1A8FDT!+9IG3% >+&]&)!,Y(-TP60#YF\T"L# BO'@'4ZN6@_R+%CE8 TUY MJH32"K%#)W()<@N -UU\!* M2OVE>A%1N(PK[+SHKP)8"H7I'0Z-!^6NGM M@B]SD-T:7P6@47SXH/*8:TOTBV"#EQN$NZI P@' SD$NK[1HQF!:YD"_R_GR M42.,(=2X2PY')3H-.)G_G1%0KD8Q0Q\37$##*'ENG4+&-K+:Z4 >%,^%WT"A]4 M/2,?_->^(*,8GE_%%_(7G3%KF) ^<8&P+@VJ^ MEI#>;HQT00LW?F'?O+ ^U /R"2X@^Y2B4L!D]@ZT-T#+!0@-I$?3PZQ*%AN7 MZ9X>)/+$'P/&*C9,I*NY>.%1L6<6]\,JG7\XNYV#Z(.7G%Y"8,(!M"#?+@$' M62G:;-0WFQ3=EX2HP.OS3,BOU5)W! >C@:?&VI\;(8)>DL2 P^K"V#!/!A/Z*CJ-3J;))!Z/^]&I8@>'\J.# M\!P!D'_WG#/(.D^FDW@Z&, 4.,%@>-06/)<6+)EN5_*]LPTG(%A=.SS)%;0R M7!HQ,1%-F/>S8E[G@)8[LD!M7 PNQVL:'Y@L]H9Q9(..66+^*5N0<>S<&)Z! MAFZWH.$0<28;@2'KUFX'EVJ6W^W+.S+?0*D4,'W92 MK$&P!;Z/ @\\"Z1LSI!"J<$H9^88'.2PBS.FA?D*KL^*=3@4A#/X[%CN#[TS M,N\4B9$!J66QV)BREH^S,E^X;V?;X'I6+/"H9H4HX4^M6701[S4@JBG<2)F= MM=$GH VER'R$+81O<^M>]*Z?J#GP-0 &;W\EPA8HW',0#VD5)_-3H+D5*Y5X MA9N+=2!FT21ZZ=%4OR^*2$00JT> MQ4\ /$JQ^TF B-_E.R.KZJ=P_9[OY^A$GI^MXN4HUI%( M4[G7^BW<\90C8E$.@JEI$E+.9%'ZJA-P^+[#;DG_7YC5 R9F+#X=0#PQ)Y@3 M:/B7=WS4:?.<+$Y:K')$++'"U")A%='A%'"(*2F]P0;N R/[$AH+<=]0= M&0%!IF0N>2&DMN)M76AO4R?ZA4BK/.S/; 09-.D[D^D;DI5L:DI7+'."++O8 MXSMFC]]%)[U345'N'C5F,;4_R>\0KJ<"8>/Z^CXZ26K/@-1#3@82DAPCA-RE MQI0P1?_4DD6&OW-?Z4K"H,$INA0*$BR"8_ B92EP[? *#BR >,OPU )/V]CX M[M0GC=Q)@4+#I^HN1X/I2W,CUVSX!$1@*;"*S9QX[9BB0]ML3C=3DIGZ(7_S[W+RR.*NY47HECQ/J+:::2_>XP1PXSSG=B<5-U M;TK8/LS*)QIVZ3R0GN 2V/R*).79"ATI;HZO6@5]U377/CXHD*@*X"&9:Z'N M1+6P ]R/LN;K,C->6KC :W:T<8P5;/&VN-L]$"_%%]\*#IW96&*+HA#Q[SER:/8< *Z[H16S!*WV1QU?#$4,ZLD$5=0-KT'#4G+5(Y;)Q:J MXJ*Y:L'M\P5)#,8B^ZT0/B MO080G)2C:@!O6BU)*Z-(K"OK!D#:K+;[$KDN=>(1N3WRQ7*1# -"WO*E81A-0")2OM#4YAG MA]Y0(46H] )X0OG' >LKK8 M$R'&Y[K>V*#!F6'(MRI"7&3+#T3L\0@7Q7ZVN]NO''#8" 78@5&T./O"4/2_ M[1?W:W8"1"8:(6?[>66D4D#=E8[>A@& NN[7P^N[#&''.;#7RTCCC+ M,$,,X$5DCRS2;F 2!R#0II#DF>4K#$ 0_5 [/]88*H-G8[F'*XM)S#K1I+RP M'EK_"8Q-(*DB!G'Y(;-N$EH&P'F6;CZ4^^UN_H@43MP[0'L*H&'L8-5GH'&0 M J1)0I%008PBD6H(]I/R0T7N, =Q25Q"Z#)*7:PLB?+'ZR/MIR(/" 9<"ZX@ M2,0)H L@**\ KMUG6#KUG%EYKP77]6)7J<4(D9R(9M802 IQ7-HZ9P04#EK M0R]_73(_"91EP!D K7=T#S1X'_(*5>8*J1C:&&,/&6GS8D5S4L2=C;FZF-$+ M+ 5MD##EZ4L =D8!7I&S/4YN1!W9>1E2 S(R692R1)>X'J=$[M)/D:',.5L3 M]T89!618SS B0;N9B24"F\.\1-0W30J7*>X"XNNR0!^FUKVMXV%%*JE1P^W& MQ?9N[2;JS1WS<43@+T@+;?\4;T(-E@"'Y6$'!]YOSAOBSV6Y?-.9#US1_& MC$!G2O)*V1!"8F2.:"L'M9F_J05!*XE!447;X#-)>$_W588"UBJ_R[RC1N*)WNI3VN#C6C]3J?"##["FFV+'LQ1&*NZNZ?<1BO;&0>*HL M2QNP(F+QM%9V[^9K-JKC-R=63CV5IR1:!#T?.JP$07]?$ =S%%#"KFRC:97[ M)%TR_;B2U2Q0G7:MP7H1>EGN%S0S34,O_M:\E1(;)&+%BBPT4M@W4/0UA>&G MY0;T8.5*),;\)&/L*<1&E%[4*BOQ.!#TR.0BSC"@093^ M\G((,,#,&!ED"A6"TB%$EK"^&'6[K(=/X]XT^:+R11TN>7#V M [%[+TVXU5>!^ZZ<=$34K=-/FPF:[UTW1 MB<:]R5G2C=4Y3WZ!X17Y7(JQF_NM^(AUR1%%[HM!P_ M(")PM\)V2?2*S%&D=<.B2Y!.\#T\Y-=,$98#+N?90Z:EC)*>\P-]O>?$0"ZA MY^09QIN8Y?0XDOC4A"=H'[I.!8I))<2(,[)QKQ0[_XAJZ;#]PK@'0FD?QUAA M1:AB8VRQ"<>D]Z.SZ,<"]W=1(.P#F;T@(=N(+&\L80N"B(Y"LZ5CEQM(1T&5 M$"B^S$2O\&):44#'VZAC6EW[B_)#EMC[CJX0<BO(#&_.HF(LS.GK1BP>]7CP9 MCB6MO$;O="Z&2*DQDDRT/"!BH=\F1:4; ^M!"=@A]I")*TIG.M^KYD'0>V!/ M.GETQ/GH 9HS6HPMUN2)XBSYVE<9#$>3"46;;TZ:([?8HHD% \+0($P6.FM^ M*684#V,3:\1QZZ2: CP!HTGHT@9YX;6HCANN:'C9)GN@6'VQV=D4! \"UJY8 MLXS1!13^5S]%,00R_CX FU5F/O;^W.TW3 XH 8_ MJ"2R80*.*1K8)*. E'-@(21@&;K!U@\\1BHY19JW"4>YY^JO.B[0H/J57E)M MP[%9&<7YSG7.02V(@G/6$!LQ8M=3&:+ZXM JN(#5D]I5$ Q<&Z^Q#FPPC1;D M^]5';78..KQP?Q1YI./,M>$/C8$N%CDA$%SFK00-DJP;\ED*%^1,=:0U MZ"7ZB($_0(_FIF"?X&\(3)2B!@BSR6HI4G5>9E)&4<:(W702"V/T?>C244J? M>*U.@E?X0*,.?0E/DMF(!&..3?LN.LG1\6WL0'HL35!5!=K1K', J$^Y.]MO MS6(Y;S&'.5@Q=Q=0R\I%P7=!$!; 1QRW8EY'[WCB4L0.C/6(CB)/9GJW0S/Z M+G"M\QW=6T O1D>FIA:4!DPXN1;IK>BM;=DVOZ%PDOOLG>PHI["7MP'!CUJ0 M%FW#[HW7**P_2CF\9-QX/"O ^;HR 1)L:^")S"WC5D M4NE'- LA#2%%;;\13-/2!X:^.2'.$C&IQ3@*FH3;GH,H9VY%C<^HYTA(]%G/?F)#6R$7+/, MX=\2(.B>RXSRF.5$#H@@80EU !*J5RGZ2MM.@Z+JP(BJX8<..5.;>-X/I3T^*(".!PDKWKTXF0YUO87C?.!/1VW4-//@H0[A M4*T?H:4T-YWGT)QG8WS $V%,+_6B#O4(AZN+VU=?_6R-$(YZ.J.BQ_:2GMKZ02/M" M>J9&LOVDAU];KP@:;S!%2GBJD0&B47= S^A_';=)/YYT>_%XW(O,IP"VIJ[K M" 8->_%H.(%/"=;!'B+6)G%WV 6,[1/F#L?P=V_H^9P\[!TFO7C:3?X9:#O" MDCTZ(/P$B[.>8J< TR,B4,@T7(N24/N8V3R#C,D]JLBAK$NX4F7=1D'5-NM/ M,NKJBB[V[?A:>A\(4!CHX184CFX0C.XWR@>C]Y>]#I%S,=SZ?'C>@HF3>##J MTZ? =_*4R;L$Q ']FE%Y:I"Z\9W.N+%R%=H9!T!.)X TSF&X_[-$_PRR#.C#'KGW9"QLG(-4X>CRMCF_C?,E?T1L![ MO5'8'2<8E7JS$& 6=S!L+@BHVBWH_D")#39PU"3+1D M;N?%8#X[Y:IB)'&E4V!1O%QIL8B(L%%>.Q/J+LXNF<@1^%.0^4LN&CY06 MR[%/Z%S$+&?:GN2TH[K!^P<"E8L%J\8BNE,ZB9(+W;.1^^<]W"A-@>1G'7ZY MWSC&3L_B3#*)DY:#H.,"F(J0.%16STL%:!P@HP)JF2R)JX#][LW&.%EU=,HIV8*A]G;]9&176OBF(1-@O@X M[@W'<;<_<0M%" :P"V2$>7BCA'_79R/S2+BKHMB_9.JMQ0N@K8&)X"(6+)J2 M(:R7UCAVKGBA)Y:MH34*L!-MTH2>:"##"6@Q).SS.( K*HV4CH'WE\^([KZ2 M? FIP?;HUEIX%L=S8DMDD::Z]KE4U[[2]^HMW:O&[S\B5IQA4R6WOD)CV+L, MW5VXR%?H)#[!WCS5J7FM"W0N >O)6&.'3[R(NIWN6/\S[@QZZJ:(ZA#1(>FU M?]M>V(#1I/E&^M^H,QH=NVKD?_%0+@,\W>?_C3O#Q$PQ1]:,SCJ*;C\!(209 M\@.G/+J^<(W*)]ZXX;,W.'48K@_246ZXS?)W.7WH8J;9\07 N]9HDZ61 [QHB+6 1 MQX5W+W)')5U%+&$D^-Z+)T; F?C'9,R@\=*#*"IB)3RYXL51Y/ -8*W(F-/KNO\UCH^*0;:AJC*H M^B )3\"*U_E.9"FN7P.OT7@J<@_P-"I7 X*C.0+U%3FO.567KOSV;/C"*97C ML62SGB=Y\L"A2Z.$_NEUHWX'R)),8N3-GLL'+;-J>U> '5N-#]^3]/AUH(8! MMSIZS3C-1.B,/&^F209VFB"3'?>?O^ZIHY^^8(8N_R2=J:71_VQ^Y>>&CC4% M&#H 'QINVZ,E);TCGH(+?0,J%*UP7'MJ*$\)=!P@P5/>H"11+[-9Z3PUB<;R MEK'S-D L?US25UR5+QD??LP=!0\Q4W4M"_I34+^?@'[OFAPNFXUY#NCU$Z/7 MU^?PBG)P7>2W4A?YS<9"OQM*Z#6L.YI\TTB?UZ$/Z3U(5O>(3+:LDQ.=E0Q8 MEZL5$Z!:K<@:=+F'NO/2;RX@=,$W<6)LEYY6V2@B7R=29\N3?I DM[ M-$&VK&S8:A;#N)D-(G#KQK'@]XXUF&-NHHXB!+IBL-J7C ]0(5'4<*O%D=$Z)]JQ'8+ MVQ-.V-K+M!2J4$R?@'?.,CCLTPY>;U8.1K_5W>XEHR^^VPSI8R^=NZ$C+IT* M7[KH:UXZN5GZ%O"MXRNEV.CSE:Z4I8$F!_")"Z:>$"0/7##6H+6<%[P(+T9, M85NOVB#N#Q+4FL;=>#+MMYKR"%$?HWX(33.:<,%GE'K<[2W=[CHBR+!QOX&4!MY:#VI(_"IM15:MP.1D:0^#SESN@-%#U-*IF!!^4V MEJ+13+ZQ6%]#8%5#1@_Q:I%X!KE==9O5$,6P6WZ+\!T?4!Y#N4UQ9PTO]'U1;CT(-^')I]QEF_ZV'D%7A'1U>X! MCOP1A.;N:>#>\.JOJ9T$FO5S6G2$U7U-?P>")<7%%M2^ $C\Z,'<;^>_H"#5)K#)'D,X8Y>OWN-VU< MFXF*^NI$9=B/IQC2VDY4T%L&VQCV@+Q,U0&BPJQT^%MQOV'_'\S\I#CX\/\F M[MKXV\A[49A^"J,,X.DW@P'1["6;NDWOBW0MO^ M/QIM/2?[[WC[WP9O03Q@O!V!*)\N[Z_FJ2#OY!R.M-K,>@[?JD'WJ M'X"WZ@G[U#\.;X^S^>C##')X#$N<'K3YC$F )2>WV'S45[7Y&.NU%A3_!Z"S ML?__CL__<'Q._LGX+ $.T_\QR%R[H$GW=V3^!R'S!-TUST)EDO[4UT/EQRA) M_L<@,M_,8[#X=]'X*V)Q,ODG8O%[)X_ YH!Q@'RH6Z^N&01_!4K6^\EGCI75 MM%/B-'AT=N^G4GO=[4J5&M3!@/&M%V"KC:2F"Y5IQ.)O@NRE MHH+9X=6?T##KA]@2JXP)JM M\#?&0?4Y,&R:ACYWE:IME;H+N:E*:6N?U/H^$!7M3>+!<" )C,"/1]T^+<=0 MM=;TKX#3HRW]RZ.7PN1K&P+Z2)2N6=A(8LR(E:!G#>O,?BT 6CTZ[:X=7OH+3N7@(X0=G\VOCU<-C^4A)^JC^$'Q$FQ]TG!S 2>#C A.K^&(2S7B\< 3B-SIQ^59%N M,?88&LSMM ,=:H/)SU,3'1B:WZ-12RK,UFSFTY3-&OUDFG16=R6D(1+EB.G* M6*HGC;8%5K_#Y6/9."KSX/K9F0Z:@DW5+M_MJ5Z)V\:HUA[=:?EB;K2Q$OLM M4T*=^50::KP";R\1'0OIU&6E7)E/1T/8XB;(IYAR9)_F4IR;J(M]J2"7KE-# MS-W2?K/PW+E*^7J=+7*N7T3U>6KW,]U9<;?1*) 9] \YEE0%D'.."X7O4A$. M;"ZH3._ \(E7/CNC26O=!W5!/%L EFO(<39YJ+4/K\-K[:GQ3VMD]?: *@UV M2CSS.B7:3"$G']^T;I3U?E=CY2[-<&B"M/XF[HMDDIK)-K+"KG1Y(JI@>D*, MA4*^,;2WU\&H]?&8/ZIW>?7A[(Z9NM-A-DHZ@\$W,";I#)-OX/_=L?PU_L;. M_[% G8F@E8QY^!3^288\>-K_AO-Z%66@4"^\0?>L-SQ+AM')U?7[EQ$%=4== M^'(:8X_4]+Y,MZ#*]TX]QDKERB3C%SN4(3?F,DB8RY!2,&,M.LS4GZ=6$Z82PLQNGT6,RE;WX5"Y M( 4&/?>,Z92$2 >I::]KR&DSGMJU?!Z,9*/:.AE5?]=1;#:4V5'%:_U*=-]X M.\*TC[_#5A!.9:D7_6D_[L)_^ <3RA<)?T4L>H\X]'>F7Q@]Y!Z.,5$$;!!D M>B![@R3KF&Z$;5PZ%BE;9"_OY51>V"\7QK2+H'$HBF[TC38YH3'*M%X3F1(U M)7.=C>E#"-!KS@D\-SF!CJUC=%JKY.:>&R:G.56>6@Z1*T\IYQ3OJ$"2EI),:*:&*U#%*5>DVTGP=M"\!EC5\O=[9D"">^= M9C'A&]RKE4%PGP 8&TF4PSR;:GKU/)8&YN3A&(<[O(54<4-%, M:CB3NLQ6W!7C,F?#%HZ\*,IMH4N0/"!0:NK.0J:BU]QFE#)WWE@F7PU2.'MN M)IZ0UGH%QHNK-WQ*.G&MN&N?F\(N*1GO8\$URZ0D&!>)IEJ%V<+L,R]ML4)I MM=1FVE5^V@>W]J0$4!)*J+BS3I*TYG"8:]@S)N"/= .S57ZOZT//J%PYZ8T8 MY>J6/.-%RL5" 0@'@)*ZP]]FI!TALG+1!9I:O\:;Q=\-=]'#Y&.&URUE)P/B MF%SCH&N6R[?2L?;.X(UG<'6"><[%G? [/XZ!R9]I .D:/'4RM#-+S,1G6,N6 M]3)T'44SH_+;5+^:$ATWTM2P&5"!6,0_;2BMS"G1JDQC."K16F8[IXP:E6CE M7BK4SSFBL@8'(='QHW9UKIJYH1/WAOY0@*B")<0V.I14C+9[P(T=+/@ M?K+!&Q*=8R=YZ2^(M8[-+?5J99+@3MNF'G$&L%[0)/YWB@]<40VUGV38:QZF3B;NL/!R8LR:[79[ M* B*F.UD/U]O5"C]OJGL:3S\9Q;W)%-<43N)Y M ;=D,II06=ZZ) +;[H^&3AI/P\;US,Q:05YZ5(CG@Z<0*],&'J?TVI4UY=DP MGTJH9MGNJ:KEM8I;!U'KNK]D;%D@XS [>>HBRUJV<4K?XR4A43J$)#6 M7!YGSB7'T;+(E-'4!5.20,ZT.M1SI"-UE8IPC7&I:D:F!^Y3GV_T&[4A-FH[ M;77H@$-@-\81YQA13GQMJW#,@%EF'W4U1I/I:B"I]V"_'W. M@66\#2">FF&K'ST!M_4Q/+B+M0?4BI4\/M043N>(KV!0:8' MJ+\F4*A(Z@DUP&NI"?[5(# 2]:N?_+80F#!-]I=W:&'CL1S--+"P0&>]<*D M[KG(C1>1VF&;C92D6M)!U^G?L)"7,<#F8I\DRYO!O"6:B6#\+YW;3G@P.V[@ M"[=AS,O+ZPOQS+R0V@$=1]CUAL(O8A"[ M'U!Z\N5-W;(7:1E(^E2Y&K^GVK],F3Q56"UR;MDN$OBCX<1GJ,Y)J(A9PV>V MX @3#BS?^D[""MZF6([U:2WO\#-8&9)0X9++KKLC2>V1GZ6KH(YIV,K/) F9 M\Z!0N602#\8CD5H&F&C<4IK_&#C$4K97-35E:@ KTA8&-F1K^#986!^O!Y(- M6[P^!CEV#MB\BB@9TM3MI5[J3$?G*"83)\@K=;]/J?J&Q<[EOIJEUE=4?^/5 MIVR^)][V%W0/@NI840P(,N2"1!6Z%=B"&4TH7.QXBVP>MR/O<%:"&B$KUF*[ MV6^X-S*#O@5=AL1GUNM\9]ML7%#)8+3'Y&U2U]!A,P<>CEZAK*_L&,\NCGN4 MMI29+D*7NO745Z0I:%/YMLS6N0@!MS#?%%(C%55;[.WG M%%+MC>-QK\=HG_0 Z_N_<4W5Z(HZZ5"3P7.W,.&O>"#P:0.4TTK"J2GE6.44G,ZRM M3D;CKDZ*;[C\Z>3M8O!9$#HD/L#+L):>UT[P8EZZ#2?M[EK($Y;LO;7Q#5]SV#@&;SQAKD1YIZWA5+%5W MBOVH8RHVS M@9H,+A0K5:WN"E1DC)'3-9FTNS%J6WAR!ADMCRLY<3V]94X\MX.23\Q/T4G+ M C$;Z''F-8!!^YO4,M3+8$ I."/[,ISBYV*Y(:6DW!3XC6,GI]\EZ-6S%>FY M=0\)MD<8'SC)62R!.NUYR.JI#E@]6\R69B,.V&ZQ-P&\Y=:.U;L2:=R5HYQN M2@LEE*0-?Z2XX^$*C-Y:+C@FR'N_:IV^46]6JC]:+(<3$K_^1NZ%Q4&0DR.= M8Z^,S1NO3N5BU;EE#QU95W2^(X5&5AN[$'=MJHX%SMX9SV+E[]V,H:K:E;E^ M&HQB1JN*%3!&KAU!YEXR!I+42KWZ %_8*-F":*T+$!Y7>SLI",96(,BD:N9C MW:'$VZH;PN %2E_HT*^'3309@N9&$BF%^9U1VQ(40+F'5P"L_"[E;,E]D4^\ M[1&9Z]@ES$U,WYC7&V@@IGL1[NW/RKFPMI-F MMY,D@\FTZU5@\4]6"IB QDB+XC9R?AU5W^S>8A5V;D:M;OB:A3QR6_B>L;QN M2\?^0;*$M,W]L7/D;;T%\0WG!<7B$05 MT&(K;%#IN:B.]<> )^"4R\B:6%* M?<'(VUJH=A\]T5[T( $5 $IJP6.:Q/B'ZJ[P!F>_X+<]M;ZP<)&0;(%1;H17 MM[;/C#9,X!F_+58YJ3(G^M-I?3;Z 71F[*#UPPK!_Y_GLXHB+/YW8RS;[E<: MN71+FF9Q>F>HJ@_5G6V>Z&>C&]FPJ"X&A[IV(\UZF86?U5DX%]4FK5KT2^4U MB?<8G%,=' O-D.NU ?M?6!NZDKZ^)I[W+34E-++B,3%[,)7ZS*D(@EM_7 L, MD7T@!4'Z0QAJ17GNCY0M_+Z5YH2E0U7E%G+&CE;8)$GW-68;K VX$MMR*J2% MZ KV1G)M$%[C1;=)4-IH\#G7ZOBNY1FE'1&.<']$Z\O-HG5MMDNOF/^IQ5BC MX@^:_[ >JM*^ S;5<;]IK72@T=Q JH%*3NW5UT[S\J.J0>*SJOFLWY#5:>+0 MUI!UDH 2WK(0-E^9\P"R]]YKY.W$ZSG10;[]4[?\<]+,J-E?NI&N?XAC, ]I*<01T3G6Y]*##7&L*;RM0\!R.OZ06G>Q"R#8FMQ'9E+GCUBCS'OZ+P MQ$J\3[A>.U'-+69"YO;IRH]$A/W#=49^?,\-YXE$L/?,)&>1')B2!J#;R9DF M=0@,4RL9]ORHZ!@ZM\"TDY]Y'YCQ^H M8HH@XE7C=;%+LBO74>55) 7G, 29]1F>@WO*I8]JEDGDD$]P =FG%--6G>:J%##-)C5ZV 0Y./S[]""1W_G![19[ MR1)LL]MLO_%0!'?D17 W0M@K58LV-_'J*.D%7I]K!Y:C 7+L )L)N-$U4B\8 M[9KSG+)]MCR?,MX>8UP@+R U.,P.R2^"?,2 ZL'L;B/(X(TXD4V?*DYBH-BH M*J(H &$<]/IG6];)C,PC&KZHCA/]_LKNY#N3U *;#0,TD2 P[KSEOPV\E@0E]%I]')-)E@AZSH M5(EZA#*%!:;?VMWQ.)Q,)_%T,( I<(+!\*@M2#*46;R.];?;J MM;F72:\NC M#@Q3SC!//K-1[2+1L,AP9YJ]NHS32\/Q,P#M["T]W":8NV]3@EAF_RE;D'G] MW-C1@?2:'O3JQ_/SMY8;L/*44YV]1HO*;T+"3O MQE9B#TL%94G9HDXFUZZ!,J>VJB*'R5]6 ,K+^7Z-[Q":S^SN).6H-20.Q1KD M8?1F 5V&9X$"SAE2*&P8Q3.0W>XLSO2AI0Z,*]U5%?0 -'+QUF9+]RWLP]Q/2L6>%2S0NP13ZU9M"'O->@49C?C61M9 M(V<5BXJ$+81O+&]5C5LKBE9.F1K<19!EM,>HF(-4R3:8^2FE3)!:BW*%6:.Q MK32#X)_8G1'W=(Q9MO#3PNQ8/^\I<"&;-^Z$!)E\9\.O0EEU!P1BW0%7 N9L M9ILZ<)-.W:1&CWUR?* .T39]=F.3SE8YQ7.=J$[-54 Y (&LRN?**G:':5&] M;;D;UD?B FG$W#Y:2[+X?5.P((1:/=J89&4J?[!:;]SPKK9/V1RNN*S1V49( M-ZH@UU,:.7/BTLUWKW@YBE4KKR\>WG&;S&Y2^[B_MX[#=K+\^;[#;LD"L3"K M!TS,UC:++XQXNZ5/9N^\P^-T?CSJ-)!M%\J7M)*9V(&<['KRM!,=QKZ))B6: M*828L$%^_)#YM3U2"AE?)?B%B+ _[,QN) M":/AG,GTG<(\=JY+2#3&X-4C M%TIX!0<60-QH>&J!I^V"?-OJDT;NI$#3X5.%Q7#8S2.09F,M( *+FU5LYM01 M>G193>Y$ROW$J?]Y)9Y>PTCWSH$/&]CB(*"/&\/8((&D'(LP3=O:>3J4$:+X MDNX8&S"B:Y]6;A VJ41>\U!.!*H8%QHHA\H/G8RA4B0J*]L+:.%@ 'JJL M0-]W@H.G=RFZ>TI M1@]E)9VOB"Q@^2'"Q!(&SJO,T#1 %_;-99Z9YXY#4O)UT<7&W30 MQL^4XYPP2KZ0BF='1QVV=AUJBSIL:/+:74$?KJR[(C10A08B#U#;?;DM*GT9 MD(@;7PC:YN!@6OTB5HE=9O,/VE@%V\L>M4W8V\0D MRB PO.9O^\6]3F,2(PDI$YS@I"5L3J8Q!L= 4H+G&-N9B.@'0(^E"2&@G6E2 M '@BOD*NYB(KJO]/^L,,!C/QO(U5TJ4 MP'RBEGEA_=W^$W,LV\(!*5@ TGJ*:!D YUFZ^5#NM[OY(])>\7 !52RHHRK) MZ+J\A> @Q561[-26D8X-:C8$:O-)2>]%,8O" CD3RS 0% ]9#Q2]EI=+BEU% M/B%,WQ/400BQ6Z097H&XOWLTNMG6V'(6V18P+ ]%982=R7HN=7BNJ&U82)-M3'HGABKDI;AI+>W6\>6,588'_+IDGAK<89G!!=IQF+P&$W+HX.IX061]LK'TU IF%7\5"=16,. MIB8ZO\<02P#(@LC$4-5^J;1$UY=?+M$)4M#$SBODN;HQ/HS-YVR:86!?;W;8 M-YC"!F0OGO7&FD-\V#&LOA!41E[5^WZ?S9<;JI&D5@!$Q'S]TUO-D=&A3"5$ M +/>_6NZWGY_";L@%S=@F-(ZO[*J1:\;!L^?L&GWV2N2IL]I=>T#% _P^3,Q M,^'/-D65-9)DOR1C#3W=P6T6.8PL01:B%1=K MUE2NK?S S$97#+GL8S=O1UM9)71?\,:?TDSB@+\A>ESJB'FQ-K7]KK0U"M@? M)O%7[-)PTGO%6>:8H5*K?(/(ML>P/]=E&TL5@*K]%H4>UF4= M:5'OKO7*T/Y\"XT'$5VMG74_P)Q5P%"GS!$M!#FMF0G+5&+,ED54HJ#6VN-Z M'!H02KEB.]XM'J'U-3=JM5D$>"0=5E],X]XTDX=\4UUMIWYJ1PF&4%1,M MT;7!3R(L/KV103?VJ[UX;Z>FJ]7!<%V9Q?"+@"587Q76A=W P&9X]7XCX1.* ME(VB$BKJ!]D$;F_8!!UPF5&Q$SS$E^9(VIC#.X1:8M.3%+:SC?L?)%9V<_4 M,=99,9P;I[LMYWU\;1VWPC_C?M2"^R^PE<]T-# ?I,C_>9N->!H/)Y-H$D\& M(P7/Q/TQ5OI/XEYO$H;_D$K[&=P5 ]LQH/]:&&]T+Z?0256O=$*8<7'[ZJO# MWUP"@-9P%$^3H?-IJ,F.#M"P6#T:#!#(YM]>5\:^O#R/AKWNGSFXEM@)',-T M1&50["<]M;USD;YS/=,7Q'[2PZ_M[4.04B\E]H 8(A>-N@-Z1O_K7,]^/.GV M@%?V(O,I@%&I:YN&04/L(SJ!3PEV"A\B9B7 I[N 57W"KN$8_NX-PQB&Y46N M=#3MR2L024ZCMY@I+E4_*;&\#>&8K!L!3.>PH_-)>-K)BF8T14*/EOSJRH+I M +'"VF(KKO9228J[GZC66IC6Y(_5^J)PYID.:ZA%1I*N8 *KY!T+9<*^6B% M1CFS\<^+G-$699'Q=1PR4,-=?J;!@&5RT-O^FB>]HDEO\#7N-[7V!=Y?]L9% MSMUS888H)<@^B0,ME\@)M2OKP73\V]:7RG14<+=K1E#("J3KJ) M^UEZKD@ :/9)M#$V"DKN$)Y%G]Z!#\)S('W2/,$O@[=B; J$-RT>1Y%?%^&< M,D-'H3^]6/G//CZW/*U%(2O(R5'^FJ&H@@X=:8!XI?L O:6 Q\;O/^)9GEVB MY=M)\VT,>Y>A#0X7^8JZ6OR5NEJ8U[K7$MA!G>Z/'<1Z$74[W;'^9]P9]-1- M$=4A4FNJ89IKM+RP6;BQ^4;ZWZ@S&AV[:KPP6+:>)H&G^_R_<6>8F"GFR&;0 M@DBQCR<]T$.X4F-TRJ/K"]<5W$Z\<<-G;W#JW% ?I*/.8'I0N/8(IONBHS!8 M%JB>7J 5&+Y3A& W7'M&_C&8>84@X3K[NG*W,[<,(^V;<1CGTNV N;?!$/[' MH$A)QL YE5%"_X"PU^_ H<@DQI+<?O^ZIPW%? M,,61?Y+.]#"&>N@@[WL.CO[328"?+S&.!)1#YQ2'IJ@8-V9->D<\->S:1O/C MVE-#>4I [D >GO(&)8DR';ZE9V@TEK>,G;SZ)?;R^CD10.I@.NX2F(CN,MQ(=1_>[9' >'9\*,2 M)6_)? _\$/(@M"[@TI; !WX8%M''/NV$(?Q'P;E#(H_S= Q2FD8L37 (V^_BQ M$)U@GI6;P%L.O.17ORL@57.:YV%4.>33>)I@'KPY#?)) D-;R'A;.'Y,U99W M_MJPROMG[^MMARK6H!+P&4939Q\OHF];]O)& M6^@=U2Z.?C!2A'#PSWPL?LJD\?7F#9I"GCO]D9:3]R!KMW!JP#$Q!HVC1?K8 M@+<>-M##DDEPG%GI!=DRFX)98\#GP_J*[1Y/_1Y]I=.\8OO!LS#+?^8W6\0@U$DP9&DP)8Y0>-WX"HXZG&" X'Z09H/)UC#VP\1I3ROQ-JPW[ M3[ZE*92&:LYS>^ \L?U66+\A6U3]I]=IV4&SL_J7?T'S=-NDA6?DTB:PIV=, MNFTSOG\HZC_]O-]THI$LI0%$]]>D">+C3S(Y?))'E8^V1O/G\8ACGWOV;?Z" MB8^ZT5\P?[NEO44! U7@\/76X_IZ7/AVVS7_R,;W)P=\-MBUG?RIW[_6N1[F M%T<]]-LLY7/Q*Y$C!151G_WPX-D_Q0*>01#Z3?4[VW:,9=>2BC#!L&ZK)N7] M.06BU6LC:3Y!C_[/ :KT!-%],]]UT'/ U+'7NL0 U;TI/G:B\=-/8G1'<'O# M5HKM_)HDK3-CN^"&HI3-[,230[\F_?:)045JZ$5;Y$[CMIF]GYM3'_!'/*UX MMEKYPYJGMO"WV ^?O[2C]$8ZLVZ?,;\!G?T]8!G_V =MGGKMOX&8.V.PC_R M'>FV_(A<7YSGC?6PJ#$-_TA(TAN&?Z0+WAL?>N?PP%:$-#0P_EI;X4V[N8WC MJ7 \49_SX"*;99N@A6?RC7?JB I-^10PX<(X3.+(ALG;JJZQ;DT2-HB_-97! MI8Q$8P!_+25"O-;7S;DRF22"#:>K1M1!:%- (/#9 M;MNOM*SVGXDQM?],S*?]9WV'6W0)VG/[ST]X.#7%;H CY*:K#^H&D2+L*@EZ M].J#IEJ>Z?6"\LSTL VEQ1/8$+/0,=C\LCMN?!EP$S:>&P]"4$B&X_"-"7IS M>D&/'#DN U\VUYE,PXN8]D-?71;V [Q2&%U 71W MXPC(.DH)_%P:<>$D'C7?.:<!5[">A;T/=[C_KG=//F!U;U!MW9>O,W2"1'P>IVS%-OY])9HYL M#/W,6=]Q4=.@0RAD(G+G"*D>?XF"^3GH4_YS6Q M ^H+2QWT-:1Q(<54RCGV@,E-.* M80F^)HQN%+6["L(IVWEX:8%,,JF0-CTT MVB*+-(\^''G/MK?GX51(Y7+[#/ZYZ9U49AJ<@N6OH&^*7N99)LI,I!C6DB/$!IS*"PT9+P<'7\LN$T9$) MTY@,>5 E%7TT?/:D9 8 A=$6E*;9/O)-D7H-G1Y.4U<[$]6 M>+0:5ZU'B@1/]F?(:CJPUKJ/Y';IF /2NI&FI@5:T[>JL87>H-8Z:I.UFWV^LT ME(OD_;OCN1Y5QU^1AE6&2P$;[89OG#WKM_UVE5!HL&=SNN@GW830G9$?>6V8 M&E'#/BFYVW*Q[B=I0E9<:3.SUW8M&RYXPU_9TJWIC7S^+!5_E<+0>E8I6=?N M*+O#'017T+^V?&/*\*K5T-#%5PJL_:37A1/NN>8+7G/STD_<SL8C DNSA_O) M:#"'E0^#^\%T."8>9(9 9A>$_#?S(',$,K\(Y&P./U_&4P^R0""+LT/^B3:? MD8>/9/AYX$.6"&1YP9YL#7R=%W(*T9&DY&_RH-94\%?7PDWU#U1S[4%> M(Y#7$2 S@)SMFH:J%R)79,;7@L/Q5!@/\@:!O(D F0/D)PFV($,I*J;\\'B+ ML-U&8"N #6RX!>V\'(+Y]QW?VB/]&-[%@G@W F8)F!,0J%C;JY.!UB XGQ#5 MS)D]XPA[0#BF2L P:W)U+[7^BSPR!4/N8V*B2<]L&H=Y;2>,D=63G2$PSZ9D]XP!O 7#$%-]3FR22 M>TX/.9D/B6DF/;-G#B&\"Y1NZ9&^4 ?P1H?Y)8TBF/37LSA7%)Y!EY"W9C6F MES2&7]+,!9Y*-HS,Z0_6HL.\DL802YH?IDD%;=6AC8OA0^5C8HI)8S@FM9+Y M:G=#P'FDUC0_!]Q/P3''9#$+89U0GM;N34P\60SQA/*T-B9FH"R&@4[E:6[,:Q\3 M,U 6PT"A;(U<^?45S$!Y# ,% U+A8V(&RF,8*(A9^IB8A?*+6JCG8Z)5M8M: MZ-K'Q"R4Q[#0'T4,D[/<P4!"S-=,Q"^4Q M+!1P.@R\CXE9*(]AH1!FNWR.62B/8:%@ZN$_FP5FH2*&A8*I1PL3LU 1PT)! M3'\*%9B%BDL6W%JR+# +%3$L%,3T95F@_^[$L-#I?-.*R,?$+%3$L% (LQ60 M"LQ"10P+A=+B-B9FH2)*$>[W,N:IU*/ +%1$J<:=KF<"K(^)6:B(4HT+% U; M@UYB%BJC5.,"1<,V)F:A,DHU+E T;&-B%BIC6"CMG:@9_I[(E9B%2F>ASO'3 MDB5;<<&64[B$ANT5K:M'1>S/X7^NHK1UY]6NKH>P[4'<2^H^!K'G.'YE\_X_ M4$L#!!0 ( ]>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/%VLUNVD 4AN%;0;Z #.=G2%*%K++)MND-6#!@%+ MSU1- M[KX.FSI2XJ\+]+'!0J!SWH7UR!KYX65TUI?0_0LB; M)IWJ?-/UJ1U_V77#J2[CUV$?^GKS6N]3T.5R%8;IC.KQ83IS\;Q=5\/S5JK% MKWK8I[*NPMLQ_.F&U]RD5'(X7^1F7##^Y;U/_[.^V^T.F_34;7Z?4EN^J/BW MH I?!^E\D-*#;#[(Z$$^'^3TH#@?%.E!J_F@%3WH=C[HEAYT-Q]T1P^ZGP^Z MIP?)$LBXY"BO06_EZ*]!;K_"LC1ZV^7HKT%OY>BO06_EZ*]!;^7HKT%OY>BO0 M6_EZ*]!;^7HKT%OY>AO0V_AZ&]#;^'H;T-NN<%:"#DOX>AO0V_AZ&]#;^'H; MT-OX>AO0V_AZ&]#;^'H;T-OX>CO0V_EZ.]#;^7H[T-OY>CO0VZ]PUHT.N_EZ M.]#;^7H[T-OY>CO0V_EZ.]#;^7H[T-OY>D>@=^3K'8'>D:]W!'I'OMX1Z!WY M>L>)WKFIA[1]*<.AW>=+EWP:_FW-!.Y MIWY$A$\O$3S^!5!+ P04 " /7G-/C*-T4=$! C( $P %M#;VYT M96YT7U1Y<&5S72YX;6S-VEU/PC 4!N"_0G9K6.G'\"/ C7JK)/H'ZG9@"]O: MM 7AW]L--=',1",D[PUC.]TY[T;S7#%[/ECRHWU3MWZ>E"'8&\9\7E*C?6HL MM;&R,J[1(9ZZ-;,ZW^@U,3&93%ENVD!M&(>N1[*8W=%*;^LPNCU>[UK/$VUM M7>4Z5*9EN[;XUG3\WC!U5/=K?%E9?Q$7)*/[?>SBX[5Y$JL^8;^8\/W&[CS> M][@CYZJ"_A3-K%953H7)MTV\)?76D2Y\212:.O6E=E0\!5>UZ_>\2^W"@VYB M8[:OV9<%Z?ERA$--PP'ZRBDGA[@M:&A47SA^\G\-_-@-N7$TMBY67:@&'B]& M6L:J9]W"4SXB=5NGH.)7PV/K\_VPK\9M^N]#+_RSZ%E_^-];/UT. 9)#@N10 M(#DRD!Q3D!R7(#FN0')<@^3@$Y0@**)R%%(YBJD -02P$"% ,4 " /7G-/ M'R// \ 3 @ "P @ $ 7W)E;',O+G)E;'-02P$" M% ,4 " /7G-/)^B'#H( "Q $ @ 'I 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( ]> M&UL4$L! A0#% @ #UYS3]0OZ>*7 @ "PH !@ M ( !]P@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% M @ #UYS3SE97:\@! KQ$ !@ ( !:A( 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ #UYS3U1X,_BU 0 MT@, !@ ( !LR$ 'AL+W=OJ]UKLP$ -(# 8 " 9XC M !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS3P4_;HFT 0 T@, !D M ( !<2< 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ #UYS3^\$H9&S 0 T@, !D ( !-"T 'AL+W=O M+P >&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS3_/X M=C*T 0 T@, !D ( !]#( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS3T)I+^.T 0 T@, !D M ( !MC@ 'AL+W=O;4! #2 P &0 @ &A.@ >&PO M=V]R:W-H965T&UL4$L! A0#% @ #UYS3Y+3Q 2U 0 T@, !D ( ! M=SX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ #UYS3P%BV+:V 0 T@, !D ( !*D4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS3TTXS''@ M 0 04 !D ( !\TH 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ #UYS3[XJD11" @ K 8 !D M ( !YU 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ #UYS3Z_ @&$ @ /04 !D ( !RU< M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#UYS3RR&J)G= 0 8P0 !D ( !(UX 'AL+W=OCJP" !+"@ &0 @ $1 M: >&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS3RJB(X&M @ [ D !D M ( !XVT 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ #UYS3]&',S%'!@ HR< !D ( !6G8 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS M3X@SNEP_ @ \ 8 !D ( !L($ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #UYS3UG3=^@ @ ,@4 M !D ( !?8@ 'AL+W=O&PO=V]R:W-H965T M'A !X;"]?7!E&UL4$L%!@ ^ #X *Y! GF $! end XML 47 R5.htm IDEA: XBRL DOCUMENT v3.19.3

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Treasury Stock

Total

Stockholders' Equity, beginning of period, Value at Dec. 31, 2017 $ 252 $ 13,017,292 $ (9,648,569) $ (1,000,000) $ 2,368,975

Stockholders' Equity, beginning of period, Shares at Dec. 31, 2017 252,393

Common stock issued for cash, Value $ 2 14,998 15,000

Common stock issued for cash, Shares 1,500

Notes payable and accrued interest converted to common stock, Value $ 11 348,092 348,103

Notes payable and accrued interest converted to common stock, Shares 10,688

Net loss (610,033) (610,033)

Stockholders' Equity, end of period, Value at Mar. 31, 2018 $ 265 13,380,382 (10,258,602) (1,000,000) 2,122,045

Stockholders' Equity, end of period, Shares at Mar. 31, 2018 264,581

Common stock issued for cash, Value $ 2 14,998 15,000

Common stock issued for cash, Shares 1,500

Notes payable and accrued interest converted to common stock, Value $ 20 365,795 365,815

Notes payable and accrued interest converted to common stock, Shares 20,236

Common stock issued for services, Value $ 6 88,794 88,800

Common stock issued for services, Shares 6,000

Net loss (726,247) (726,247)

Stockholders' Equity, end of period, Value at Jun. 30, 2018 $ 293 13,849,969 (10,984,849) (1,000,000) 1,865,413

Stockholders' Equity, end of period, Shares at Jun. 30, 2018 292,317

Notes payable and accrued interest converted to common stock, Value $ 34 308,875 308,909

Notes payable and accrued interest converted to common stock, Shares 34,371

Net loss (608,519) (608,519)

Stockholders' Equity, end of period, Value at Sep. 30, 2018 $ 327 14,158,844 (11,593,368) (1,000,000) 1,565,803

Stockholders' Equity, end of period, Shares at Sep. 30, 2018 326,688

Stockholders' Equity, beginning of period, Value at Dec. 31, 2018 $ 430 14,695,403 (12,462,814) (1,000,000) 1,233,019

Stockholders' Equity, beginning of period, Shares at Dec. 31, 2018 429,720

Compensation for vested stock options 1,025 1,025

Notes payable and accrued interest converted to common stock, Value $ 293 548,515 548,808

Notes payable and accrued interest converted to common stock, Shares 293,455

Net loss (559,397) (559,397)

Stockholders' Equity, end of period, Value at Mar. 31, 2019 $ 723 15,244,943 (13,022,211) (1,000,000) 1,223,455

Stockholders' Equity, end of period, Shares at Mar. 31, 2019 723,175

Notes payable and accrued interest converted to common stock, Value $ 72 355,519 355,591

Notes payable and accrued interest converted to common stock, Shares 71,933

Amounts due to related parties converted to common stock, value $ 2 4,998 5,000

Amounts due to related parties converted to common stock, shares 2,000

Net loss (570,365) (570,365)

Stockholders' Equity, end of period, Value at Jun. 30, 2019 $ 797 15,605,460 (13,592,576) (1,000,000) 1,013,681

Stockholders' Equity, end of period, Shares at Jun. 30, 2019 797,108

Net loss (373,749) (373,749)

Stockholders' Equity, end of period, Value at Sep. 30, 2019 $ 797 $ 15,605,460 $ (13,966,325) $ (1,000,000) $ 639,932

Stockholders' Equity, end of period, Shares at Sep. 30, 2019 797,108

XML 48 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 19, 2019
Document and Entity Information:
Entity Registrant Name	Clinigence Holdings, Inc.
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Entity Central Index Key	0001479681
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		4,627,721
Entity Filer Category	Non-accelerated Filer
Entity's Reporting Status Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Ex Transition Period	false
Entity Shell Company	false
File Number	000-55462
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3

XML 49 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Going Concern

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 3 - Going Concern

Note 3 – Going Concern

XML 50 R36.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Office equipment and fixtures	$ 10,964	$ 10,964
Less: accumulated depreciation	9,588	8,846
Property, Plant and Equipment, Net	$ 1,376	$ 2,118

XML 51 R32.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details 1)	9 Months Ended
	Sep. 30, 2019
Office equipment and fixtures \| Minimum
Office equipment useful life	5 years
Office equipment and fixtures \| Maximum
Office equipment useful life	7 years
Computer hardware
Office equipment useful life	5 years
Computer software
Office equipment useful life	3 years
Development equipment
Office equipment useful life	5 years

XML 52 R19.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations and Credit Risk

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 13 - Concentrations and Credit Risk

Note 13 – Concentrations and Credit Risk

Sales and Accounts Receivable

Cash

XML 53 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 5 - Intangible Assets

Note 5 – Intangible Assets

Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at September 30, 2019 and December 31, 2018:

	2019		2018
Software	$	156,925	$	156,925	5 years
Customer contracts		644,846		644,846	10 years
FDA 510K clearance		1,396,000		1,396,000	5 years
Technology license		1,000,000		1,000,000	5 years
In process research and development		604,000		604,000	Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		1,751,658		1,229,756
	$	2,050,113	$	2,572,015

Amortization expense of $521,902 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

XML 54 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Derivative Liability

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Note 9 - Derivative Liability

Note 9 – Derivative Liability

	September 30,	December 31,
	2019	2018
Annual dividend yield	—	—
Expected life (years)	0.78 - 1.0	0.77 - 1.0
Risk-free interest rate	2.44% - 2.52%	2.07% - 2.57%
Expected volatility	274% - 294%	257% - 293%

XML 55 R53.htm IDEA: XBRL DOCUMENT

Note 16- Subsequent Events (Details Narrative)		1 Months Ended
Note 16- Subsequent Events (Details Narrative)	Aug. 08, 2019	Oct. 25, 2019
Reverse stock split		1-for-500
Clinigence Holdings
Reverse stock split	1 for 500

XML 56 R37.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disclosure Text Block [Abstract]
Depreciation expense	$ 742	$ 1,295

XML 57 R33.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details 2)	9 Months Ended
	Sep. 30, 2019
Software
Intangible assets useful life	5 years
Technology license
Intangible assets useful life	5 years
In process research and development
Intangible assets useful life	Indefinite
Customer contracts
Intangible assets useful life	10 years

XML 58 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 4 - Property and Equipment

Note 4 – Property and Equipment

Property and equipment are carried at cost and consist of the following at September 30, 2019 and December 31, 2018:

	2019		2018
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		9,588		8,846
	$	1,376	$	2,118

Depreciation expense of $742 and $1,295 was charged to operations for the nine months ended September 30, 2019 and 2018, respectively.

XML 60 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Convertible Debt

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 8 - Convertible Debt

Note 8 – Convertible Debt

Convertible Notes Payable

Convertible notes payable at September 30, 2019 and December 31, 2018 are summarized as follows:

	2019		2018
Total face value of notes	$	75,000	$	478,957
Less: Discount		2,454		101,346
Balance	$	72,546	$	377,611

XML 61 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Income Taxes

9 Months Ended

Sep. 30, 2019

Disclosure Text Block [Abstract]

Note 12 - Income Taxes

Note 12 - Income Taxes

ZIP 62 0001607062-19-000457-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-19-000457-xbrl.zip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htm IDEA: XBRL DOCUMENT v3.19.3

Note 15 - Commitments and Contingencies (Details Narratives) - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Disclosure Text Block [Abstract]

Rent expense $ 17,711 $ 21,363

Term 3 years

Base Salary $ 75,000

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Treasury Stock	Total
Stockholders' Equity, beginning of period, Value at Dec. 31, 2017	$ 252	$ 13,017,292	$ (9,648,569)	$ (1,000,000)	$ 2,368,975
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2017	252,393
Common stock issued for cash, Value	$ 2	14,998			15,000
Common stock issued for cash, Shares	1,500
Notes payable and accrued interest converted to common stock, Value	$ 11	348,092			348,103
Notes payable and accrued interest converted to common stock, Shares	10,688
Net loss			(610,033)		(610,033)
Stockholders' Equity, end of period, Value at Mar. 31, 2018	$ 265	13,380,382	(10,258,602)	(1,000,000)	2,122,045
Stockholders' Equity, end of period, Shares at Mar. 31, 2018	264,581
Common stock issued for cash, Value	$ 2	14,998			15,000
Common stock issued for cash, Shares	1,500
Notes payable and accrued interest converted to common stock, Value	$ 20	365,795			365,815
Notes payable and accrued interest converted to common stock, Shares	20,236
Common stock issued for services, Value	$ 6	88,794			88,800
Common stock issued for services, Shares	6,000
Net loss			(726,247)		(726,247)
Stockholders' Equity, end of period, Value at Jun. 30, 2018	$ 293	13,849,969	(10,984,849)	(1,000,000)	1,865,413
Stockholders' Equity, end of period, Shares at Jun. 30, 2018	292,317
Notes payable and accrued interest converted to common stock, Value	$ 34	308,875			308,909
Notes payable and accrued interest converted to common stock, Shares	34,371
Net loss			(608,519)		(608,519)
Stockholders' Equity, end of period, Value at Sep. 30, 2018	$ 327	14,158,844	(11,593,368)	(1,000,000)	1,565,803
Stockholders' Equity, end of period, Shares at Sep. 30, 2018	326,688
Stockholders' Equity, beginning of period, Value at Dec. 31, 2018	$ 430	14,695,403	(12,462,814)	(1,000,000)	1,233,019
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2018	429,720
Compensation for vested stock options		1,025			1,025
Notes payable and accrued interest converted to common stock, Value	$ 293	548,515			548,808
Notes payable and accrued interest converted to common stock, Shares	293,455
Net loss			(559,397)		(559,397)
Stockholders' Equity, end of period, Value at Mar. 31, 2019	$ 723	15,244,943	(13,022,211)	(1,000,000)	1,223,455
Stockholders' Equity, end of period, Shares at Mar. 31, 2019	723,175
Notes payable and accrued interest converted to common stock, Value	$ 72	355,519			355,591
Notes payable and accrued interest converted to common stock, Shares	71,933
Amounts due to related parties converted to common stock, value	$ 2	4,998			5,000
Amounts due to related parties converted to common stock, shares	2,000
Net loss			(570,365)		(570,365)
Stockholders' Equity, end of period, Value at Jun. 30, 2019	$ 797	15,605,460	(13,592,576)	(1,000,000)	1,013,681
Stockholders' Equity, end of period, Shares at Jun. 30, 2019	797,108
Net loss			(373,749)		(373,749)
Stockholders' Equity, end of period, Value at Sep. 30, 2019	$ 797	$ 15,605,460	$ (13,966,325)	$ (1,000,000)	$ 639,932
Stockholders' Equity, end of period, Shares at Sep. 30, 2019	797,108

Note 9 - Derivative Liability (Details)	9 Months Ended
Note 9 - Derivative Liability (Details)	Sep. 30, 2019	Sep. 30, 2018
Annual dividend yield	0.00%	0.00%
Minimum
Expected life (years)	9 months 11 days	9 months 7 days
Risk-free interest rate	2.44%	2.07%
Expected volatility	274.00%	257.00%
Maximum
Expected life (years)	1 year	1 year
Risk-free interest rate	2.52%	2.57%
Expected volatility	294.00%	293.00%

Note 7 - Stock Based Compensation (Details 2) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Text Block [Abstract]
Warrants, Outstanding, Beginning Balance	1,875,000	400,000
Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.12	$ 0.62
Warrants, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.12	$ 0.10
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 2 months 27 days	3 years 3 months 8 days
Warrants, Granted		1,500,000
Warrants, Granted, Weighted Average Exercise Price		$ 0.05
Warrants expired	(250,000)
Warrants expired, Weighted Average Exercise Price	$ 0.73
Warrants, Outstanding, Ending Balance	1,625,000	1,900,000
Warrants, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.03	$ 0.21
Warrants, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.12
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	2 years 10 months 25 days	3 years 5 months 27 days